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Paraneoplastic neurologic diseases (PNDs) arise when systemic 
malignancies express proteins normally restricted to neurons. Abnormal 
expression of a neuronal protein by tumor cells in the periphery results 
in an autoimmune response that then targets both the tumor and the 
nervous system. These diseases offer a unique opportunity to gain 
insight into the mechanisms behind both tumor immunity and neuronal 
autoimmunity.  The Hu syndrome is an example of PND that affects 
patients with small cell lung cancer (SCLC).    Hu patients are diagnosed 
by the presence of antibodies in the blood that recognize the HuD 
antigen.  HuD is normally restricted in expression to neurons of both the 
peripheral and central nervous systems, but ectopically expressed by 
SCLCs.   Despite its expression in virtually all SCLCs, only a small 
fraction of SCLC patients go on to develop neurologic disease.  These 
patients mount an impressive immune response to their cancer that 
results in remarkable tumor immunity to this typically aggressive 
malignancy.   Although antibodies to HuD are important diagnostic 
criteria for the disease, they are not sufficient for disease pathogenesis. 
Because HuD is an intracellular protein, CD8 T cells are more prone to 
mediate the destruction of HuD-expressing SCLC cells and neurons.   We 
previously demonstrated that patients with paraneoplastic cerebellar 
degeneration (PCD), another form of PND, harbor CD8 T cells specific for 
the onconeural antigen Cdr-2, suggesting that CD8 T cells mediate 
tumor immunity and neuronal degeneration in these patients.   To study 
the CD8 T cell response to HuD, we performed an exhaustive screen of 
the entire HuD peptide library to identify the immunodominant murine 
CD8 T cell epitope of the protein.    We showed that mice are peripherally 
tolerized to this neuron-specific protein, which could help to explain why 
most SCLC patients remain neurologically intact despite tumor 
expression of HuD.   In addition, HuD-specific CD8 T cells were able to 
traffic to the central nervous system in an adoptive transfer model, 
however these cells were not sufficient to induce neurologic degeneration.   
To translate these results to the clinic, we screened the HuD peptide 
library over 8 human MHC I alleles in order to define HLA-restricted 
epitopes of the protein.  This lead to the discovery of two human CD8 T 
cell epitopes of HuD.  Using tetramers specific for these HLA-restricted 
epitopes, we demonstrated that patients with the Hu syndrome harbor 
cytotoxic HuD-specific CD8 T cells in their blood.    By combining our 
results from the clinic with the mouse system we are closer to 
understanding how the immune system is able to mediate both tumor 
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CHAPTER I. INTRODUCTION 
 
Paraneoplastic neurologic degenerations (PNDs) 
Paraneoplastic neurologic degenerations (PNDs) offer a unique 
opportunity to gain insight into the mechanisms behind tumor immunity 
and neuronal autoimmunity.  These diseases arise when systemic 
malignancies express proteins normally restricted to neurons.  Abnormal 
expression of a neuronal protein by tumor cells in the periphery results 
in an autoimmune response that then targets both the tumor and the 
nervous system.   PNDs are arguably the most well documented 
examples of naturally occurring tumor immunity, most commonly 
associated with breast, ovarian and lung tumors.  The tumor immunity 
generated is so effective that PND patients often present first with 
neurologic symptoms before their cancer is diagnosed. It is important to 
note that the majority of cancer patients never mount a detectable 
immune response to their tumor, but in this small subset of PND 
patients (0.01%) the immune system responds to the cancer, resulting in 
both remarkable tumor immunity as well as autoimmune neurologic 
degeneration (Fig 1). 
 
The immune response to neuronal proteins ectopically expressed by 
tumor cells in PND patients serves to connect their tumor immunity and 
neuronal degeneration.  Evidence for an immune-mediated disease came  
2 
Fig 1. Model of anti-Hu syndrome. The presence of a small cell lung 
cancer tumor in the periphery that expresses HuD results in an immune 
response to the HuD protein that is able to respond to the tumor, 
resulting in tumor immunity, and traffic to the nervous system to target 
HuD-expressing neurons, resulting in neuronal degeneration. 
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from the identification of high titer antibodies in the blood and 
cerebrospinal fluid of PND patients (Graus, Elkon et al. 1986; Furneaux, 
Reich et al. 1990). Patient antibodies were used to identify so-called 
onconeural proteins aberrantly expressed by tumors and naturally found 
in the nervous system.    
 
Although the presence of high titer autoantibodies in PND patients serves 
as a diagnostic tool, their role in disease pathogenesis remains unclear.   
Onconeural antigens are intracellular proteins and therefore not easily 
accessible to circulating antibodies.   Furthermore, attempts to establish 
animal models of disease based on the generation of high titer antibodies 
to onconeural antigens have failed (Sakai, Gofuku et al. 1995; Sillevis 
Smitt, Manley et al. 1995).  Given the intracellular nature of the PND 
antigens, it seems likely that T cells play an important role in disease 
pathogenesis.  This is evidenced by the presence of lymphocytic 
infiltrates into relevant regions of the CNS in PND brains obtained at 
autopsy (Jean, Dalmau et al. 1994; Verschuuren, Chuang et al. 1996).   
Clear evidence for T cell involvement in disease pathogenesis has been 
demonstrated for paraneoplastic cerebellar degeneration (PCD), a 
particular type of PND that affects women with breast and ovarian 
cancer.   Patients with PCD have high titer antibody to Cdr2, an 
intracellular protein normally expressed exclusively by Purkinje cells in 
the cerebellum.  Freshly isolated CD8 T cells from the blood of PCD 
4 
patients have been shown to kill Cdr2-expressing targets in a cytotoxic T 
lymphocyte (CTL) assay, and activated T cells are found in the 
cerebrospinal fluid of PCD patients (Albert, Darnell et al. 1998; Albert, 
Austin et al. 2000).     Taken together, this evidence suggests that T cells 
play a critical role in the pathogenesis of PCD.  
 
Anti-Hu Syndrome 
Like PCD, anti-Hu syndrome (also referred to as subacute sensory 
neuropathy/encephalomyelitis) is a particular form of PND characterized 
by neuronal loss and inflammatory infiltrates of the nervous system 
(Henson, Hoffman et al. 1965; Horwich, Cho et al. 1977; Anderson, 
Cunningham et al. 1987).  Patients with anti-Hu syndrome develop 
neurologic symptoms that affect discrete areas of the nervous system 
including the dorsal root ganglia, limbic system, cerebellum, brainstem, 
motor or autonomic nervous system.   Most patients go on to develop 
multifocal neuronal degeneration and die from neuronal causes, on 
average, seven months after diagnosis (Dalmau, Graus et al. 1992).  
Antisera from patients recognize the Hu antigen, which is normally 
restricted to neurons of both the peripheral and central nervous systems.  
Anti-Hu syndrome is associated with Small Cell Lung Cancer (SCLC) and 
patients are able to generate impressive tumor immunity to this typically 
aggressive malignancy.  SCLCs from anti-Hu patients are usually limited 
to single nodules, which are discovered only after presentation of 
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neurologic symptoms (Dalmau, Graus et al. 1992).   Although very few 
SCLC patients go on to develop PND (0.01%), all SCLCs express the Hu 
antigen (Manley, Smitt et al. 1995).  The presence of high titer antibody 
to Hu allows for diagnosis of anti-Hu syndrome and is correlated with 
natural tumor immunity.  Apart from the small cohort of SCLC patients 
with the Hu syndrome, 15% of SCLC tumors generate a low titer anti-Hu 
antibody response in the absence of neurologic disease (Dalmau, 
Furneaux et al. 1990).  Patients with low titer antibodies have limited 
stage tumors and better prognoses compared to SCLC patients with no 
detectable Hu antibodies (Dalmau, Furneaux et al. 1991; Graus, Dalmou 
et al. 1997).   Uncovering the differences between high titer, 
neurologically affected PND patients and low titer, neurologically normal 
SCLC patients will undoubtedly improve our understanding of the 
mechanisms behind both tumor immunity and neuronal autoimmunity.    
 
The Hu antigen recognized by patient antisera is part of a protein family 
consisting of four members: HuA, HuB, HuC, and HuD.  Hu family 
members are highly homologous to a Drosophila nuclear protein ELAV.  
Deletion mutants of elav are embryonic lethal due to abnormal neuronal 
development (Robinow, Campos et al. 1988; Robinow and White 1991).   
The sequence of Hu genes is highly conserved between individual Hu 
family members within and across species (Okano and Darnell 1997).   
The Hu proteins bind to RNA, and are found in the nuclei of neurons of 
6 
both the peripheral and central nervous systems (Ma, Cheng et al. 1996; 
Keene 1999).  HuA is the ancestral Hu gene, and unlike HuB, HuC, and 
HuD, is ubiquitously expressed throughout the body (Ma, Cheng et al. 
1996; Okano and Darnell 1997).  HuB, HuC, and HuD are restricted to 
neurons, and all neurons contain one or more of the Hu proteins; for 
example, the dorsal root ganglia contain all three Hu proteins whereas 
Purkinje cells in the cerebellum contain HuC exclusively (Okano and 
Darnell 1997).   Antisera from patients with the Hu syndrome react with 
HuB, HuC, and HuD however only HuD is expressed by SCLCs (Manley, 
Smitt et al. 1995).    HuD, then, appears to be the antigen responsible for 
initiating an autoimmune response to SCLC in the periphery.  This HuD-
specific immune response is then able to traffic to the nervous system 
and target neurons expressing the Hu antigen.  Patients with the Hu 
syndrome present first with neurologic disease affecting one region of the 
nervous system but go on to develop multifocal neurologic degeneration.   
If the initial autoimmune attack is directed against HuD specifically, it 
may spread to other Hu family members and target neurons expressing 
various combinations of the Hu proteins.   
 
There is no difference between the HuD gene expressed by SCLCs and by 
neurons (Carpentier, Voltz et al. 1998).  Histologic characteristics of 
tumors found in PND patients are no different from those in 
neurologically normal SCLC patients except that they may be heavily 
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infiltrated with inflammatory cells (Rosenblum 1993).  Thus, the 
initiation of an autoimmune response to HuD does not rely on some 
deviation in the protein or tumor in anti-Hu patients.  Importantly, 
patients with the Hu syndrome do not succumb to peripheral 
autoimmunity and tissues outside of the nervous system are never 
attacked.  If the ultimate autoimmune response is able to recognize other 
Hu family members in addition to HuD, it should not recognize HuA, as 
this would lead to massive peripheral autoimmunity given HuA’s 
ubiquitous expression pattern.     
 
The autoimmune response to Hu is evidenced by the presence of 
autoantibodies in the blood and cerebrospinal fluid of anti-Hu patients, 
however given that the Hu proteins are sequestered within the nuclei of 
neurons, it seems unlikely that antibodies play a dominant role in 
disease pathogenesis.  Rather, T cells specific for HuD are more apt to 
generate anti-tumor immunity and neuronal degeneration.  Cell mediated 
autoimmunity is suggested by the presence of activated T cell in the 
cerebrospinal fluid of anti-Hu patients.    Moreover, the immune 
response in patients is Th1-skewed, with Th1 CD4 helper T cells and 
IgG1 antibodies present in circulation (Jean, Dalmau et al. 1994; 
Benyahia, Liblau et al. 1999).   Attempts to create mouse models of the 
disease by immunizing with whole HuD protein fail to induce neuronal 
autoimmunity despite the generation of high titer antibodies to Hu 
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(Sillevis Smitt, Manley et al. 1995).   For these reasons, T cells appear to 
play an essential role in the Hu syndrome, and understanding the 
mechanisms behind tumor immunity and neuronal autoimmunity 
should focus on the T cell response to the Hu antigen.   
 
Anti-Hu syndrome is an aggressive illness.  Prognosis is usually poor 
because disease involves irreversible neuronal loss and evolves 
subacutely so that intervention is delayed.  When the syndrome is 
diagnosed, treatment of this presumably T cell mediated PND relies on 
an immunosuppressant like tacrolimus and elimination of the underlying 
SCLC tumor (Albert, Austin et al. 2000).   To date, there is no known 
immunogenic epitope of the HuD protein, which severely limits our 
ability to examine T cell responses to HuD in patients with the Hu 
syndrome.  In order to more effectively diagnose and treat patients with 
this aggressive autoimmune disease, we must identify immunogenic 
epitopes of HuD so that we can isolate and study T cells specific for this 
antigen.   
 
Tolerance mechanisms to self-antigens 
HuD is a self-protein naturally expressed by neurons.  To understand 
how the body generates autoimmunity against HuD, it is important to 
understand the mechanisms responsible for tolerance induction.  
Tolerance is the body’s defense against reactivity to self.  Lack or loss of 
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tolerance leads to immune responses against self-proteins, eventually 
resulting in clinical autoimmune disease.  The induction and 
maintenance of tolerance involves interactions between antigen 
presenting cells (APC) and lymphocytes (Pugliese 2004).  Central 
tolerance happens in the thymus and is responsible for purging the T cell 
repertoire of self-reactive clones (Gallegos and Bevan 2004) (Starr, 
Jameson et al. 2003).   Ideally, any lymphocyte capable of recognizing 
self-peptide is eliminated during development, sculpting an immune 
system that is armed with T cells specific only for foreign antigens.   The 
thymic architecture is designed to ensure that mature T cells emerge 
from the thymus with the ability to recognize self-MHC molecules but not 
self-peptides.  Cortical thymic epithelial cells (cTECs) are responsible for 
positive selection of lymphocytes whereas medullary thymic epithelial 
cells (mTECs) delete autoreactive cells.  This process is imperfect, 
however, and self-reactive clones escape into the periphery where there is 
potential recognition of self-tissue (Gallegos and Bevan 2006) (Bouneaud, 
Kourilsky et al. 2000).   In order to silence these self-specific T cells and 
avoid autoimmune disease, peripheral tolerance exists.   The 
mechanisms responsible for peripheral tolerance are varied and can act 
directly on T cells, through their deletion or inactivation, or through 





The role of central tolerance in preventing autoimmunity was highlighted 
by the discovery of AIRE, a transcription factor expressed in the thymus 
that controls the ectopic expression of tissue-specific antigens by mTECs 
(Holmdahl 2007).  Thymic stromal cells do not endogenously express 
proteins normally restricted in expression to particular organs.  AIRE, 
and perhaps other undiscovered transcription factors are responsible for 
driving expression of these tissue-specific antigens in the thymus for 
deletion of autoreactive T cell clones.  AIRE was first identified as the 
underlying gene responsible for the human autoimmune disorder termed 
APECED (Peterson, Nagamine et al. 1998).   Patients with APECED (for 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy) 
develop multiorgan autoimmune disease due to a lack of functional AIRE 
protein.  As in humans, loss of AIRE in mice leads to the development of 
multiorgan autoimmune disease that is dependent on the absence of 
AIRE from thymic stromal cells (Liston, Lesage et al. 2003) (Anderson, 
Venanzi et al. 2002).   The ectopic expression of tissue-restricted 
antigens by AIRE in the thymus is necessary for the deletion of self-
specific T cell clones and protection against autoimmune disease.  
Recently, it was suggested that the role of AIRE in preventing 
autoimmunity be extended to include deletion of autoreactive T cells in 
the periphery.  AIRE was shown to be expressed in lymph node stromal 
cells in a transgenic mouse model of tolerance induction.  Ectopic 
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expression of tissue-restricted antigens in the lymph nodes resulted in 
elimination of self-reactive T cell clones (Lee, Epardaud et al. 2007).  In 
this model, a cytosolic form of ovalbumin (OVA) under the control of a 
tissue-specific promoter was endogenously processed and presented onto 
MHC I molecules by a stromal cell population in the lymph node cortex. 
Endogenous presentation of OVA in the lymph node was an effective 




Peripheral tolerance is designed to suppress the activity of self-specific T 
cell that have escaped thymic deletion.  The mechanisms responsible for 
peripheral tolerance can be distinguished between those that act on 
responding T cells directly and those that rely on additional cell types, 
namely regulatory T cells.   T-cell intrinsic mechanisms include 
ignorance, anergy, and activation-induced cell death (Walker and Abbas 
2002).  Ignorance is achieved by sequestering tissue-specific antigens in 
areas not easily accessed by lymphocytes (Alferink, Tafuri et al. 1998).   
Limiting the amount of antigen in the periphery is also an important 
means of maintaining T cell ignorance, since there is a threshold below 
which T cells are unable to respond (Kurts, Miller et al. 1998).    Anergy 
is the functional inactivation of a T cell upon encounter with antigen.  
Inhibitory receptors, most notably CTLA-4 and PD-1, are responsible for 
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inducing anergy in response to T cell receptor (TCR) ligation.  CTLA-4 on 
the surface of T cells binds to the co-stimulatory molecules B7-1 and B7-
2, and was shown to be critical for anergy induction in vivo (Perez, Van 
Parijs et al. 1997).  PD-1 is highly expressed on the surface of anergic T 
cells, and mice lacking this receptor develop autoimmune disorders 
(Nishimura, Nose et al. 1999). Activation-induced cell death and anergy 
depend on T cell recognition of MHC-peptide complexes on APCs so that 
APCs, particularly dendritic cells, play an important role in maintaining 
tolerance in the periphery.    Activation-induced cell death is arguably 
the most effective means of preventing autoimmunity since it results in 
the elimination of self-specific T cell clones from the repertoire.    
Because self-antigens naturally persist instead of being cleared from the 
body, autoreactive T cells that repetitively engage their TCR may be 
subject to apoptosis via activation-induced cell death.    Ligation of the 
Fas death receptor is critical to this pathway, and defects in Fas 
signaling are associated with human autoimmune lymphoproliferative 
syndrome (ALPS) (Fisher, Rosenberg et al. 1995).  
 
Experimental evidence has shown that bone marrow derived APCs and 
not the peripheral tissue itself are responsible for inducing peripheral 
tolerance (Kurts, Heath et al. 1996; Kurts, Kosaka et al. 1997).   
Recognition of MHC-peptide complexes on APCs by T cells specific for 
tissue-restricted antigens results in tolerization, either though deletion or 
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anergy (Heath, Kurts et al. 1998) (Redmond and Sherman 2005).  Using 
a transgenic model of peripheral tolerance induction in which OVA is 
expressed in the pancreas and kidney, it was shown that naïve 
transgenic OVA-specific CD8 T cells undergo tolerance in the form of 
deletion as a result of OVA presentation in the periphery.  Deletion was 
preceded by an initial period of activation and proliferation that did not 
translate into effective priming (Kurts, Kosaka et al. 1997).   Like CD8 T 
cells, CD4 T cells are tolerized in the periphery by APCs that have 
acquired exogenous antigen (Heath, Kurts et al. 1998).  In transgenic 
mice that express hemagglutinin (HA) in various parenchymal cells, HA-
specific CD4 T cells are anergized by presentation of HA on bone marrow 
derived APCs (Adler, Marsh et al. 1998).   Bone marrow derived APCs 
play a pivotal role in maintaining tolerance in the periphery to both CD4 
and CD8 T cell epitopes.   Experimental evidence indicates that myeloid 
DCs in particular are responsible for tolerance induction (Albert, 
Jegathesan et al. 2001).   DCs are exceptionally adept at antigen 
processing and presentation, with the capacity to take up antigens and 
present them to T cells as peptides bound to MHC I and II molecules 
(Mellman and Steinman 2001).  Compared to other antigen presenting 
cells, DCs are more effective at stimulating naïve T cells and shaping the 
quality of immune responses.   The types of antigens captured and 
presented by DCs include both foreign and self-proteins.   Activation of T 
cells to foreign antigens is required for effective clearance of invading 
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pathogens. Conversely, suppression of T cells specific for self-antigens is 
necessary for the prevention of autoimmunity.  DCs do not endogenously 
express tissue-specific proteins and must therefore capture peripheral 
tissue for processing and presentation of self-peptides onto MHC I and 
MHC II molecules.  To this end, DCs utilize a pathway termed cross 
presentation that allows exogenous antigen to be presented on MHC I as 
well as MHC II molecules to CD8 and CD4 T cells, respectively (Mellman 
and Steinman 2001).   The factors that determine whether DC epitope 
presentation will result in priming or tolerization are still unclear.   For 
CD8 T cell priming via cross-presentation by a DC, it was shown that 
cognate CD4 T cells are required for the generation of a productive 
immune response (Albert, Jegathesan et al. 2001).   The absence of 
cognate CD4 T cell help resulted in tolerance of CD8 T cells.  A 
coordinated response by CD8 and CD4 T cells is therefore necessary for 
the initiation of an effective immune response, and activation of cognate 
CD4 T cells is an important checkpoint for CD8 T cell priming.   
 
The maintenance of peripheral tolerance depends on a persistent source 
of antigen.  Both transgenic and non-transgenic systems have been used 
to study the mechanisms behind peripheral tolerance induction.  The 
non-transgenic model of peripheral tolerance to the murine ovarian-
specific antigen ZP3 highlights the requirement for a constant source of 
antigen in the periphery (Garza, Agersborg et al. 2000).  Females are 
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naturally tolerized to ZP3, requiring 100-fold more antigen to elicit an 
immune response compared to males.  Tolerance in females was shown 
to depend on the presence of endogenous ZP3, as removal of the ovaries 
from neonates converted the female immune response into that of males.  
Moreover, exposure to neonatal antigen was insufficient for the 
maintenance of tolerance, which required a constant source of antigen 
throughout adulthood.  When the ovaries were removed from adult 
females that then received syngeneic ovarian implants followed by 
immunization to ZP3, the mice developed overt ovarian autoimmune 
disease.  Normal females given ovarian implants and immunized to ZP3 
maintained tolerance to the antigen and did not exhibit autoimmunity.  
 
Regulatory T cells 
Regulatory T cells are a specialized population of cells critical to the 
maintenance of peripheral tolerance.   Peripheral tolerance induction by 
regulatory T cells is achieved by active suppression of effector T cells.  
Most regulatory T cells are classified as CD4+CD25+ cells that express the 
transcription factor FoxP3, and in both humans and mice represent less 
than 10% of the total CD4 T cell population (Akbar, Vukmanovic-Stejic et 
al. 2007).  There are two distinct classes of regulatory T cells, 
distinguished by their developmental course.  Natural regulatory T cells 
emerge from the thymus as FoxP3+ cells with the intrinsic ability to 
inhibit the proliferation of activated T cells, whereas induced or adaptive 
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regulatory T cells are converted from activated effector or memory CD4 T 
cells in the periphery (Itoh, Takahashi et al. 1999; Akbar, Vukmanovic-
Stejic et al. 2007). Production of natural regulatory T cells occurs 
through presentation of self-peptides in the thymus.   The precise signals 
leading to the generation of natural regulatory T cells, as opposed to the 
deletion of self-specific thymocytes, are not well understood (Picca and 
Caton 2005) (Apostolou, Sarukhan et al. 2002).    Both pathways require 
recognition of self-peptide in the thymus by developing lymphocytes, 
however the type of APC responsible for antigen presentation, as well as 
the strength of the TCR-MHC interaction, may help to determine the fate 
of self-reactive T cells.   
 
A peripheral source of self-antigen is required for the maintenance of 
effective regulatory T cells from thymic emigrant precursors (Picca and 
Caton 2005).  Natural regulatory T cells emerge from the thymus with an 
intrinsic ability to suppress effector T cells, however their survival 
depends on continual exposure to antigen in the periphery.  This has 
been demonstrated in a non-transgenic model of autoimmune thyroiditis 
(Seddon and Mason 1999).  Autoimmune thyroiditis results in high titer 
antibodies against thyroglobulin and extensive leukocytic infiltration of 
the thyroid glands.  Development of disease can be prevented by 
reconstitution with natural regulatory T cells.  In order to study the 
dependency of these regulatory T cells on peripheral antigen, the thyroid 
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was ablated in utero before the emergence of T cells from the thymus so 
that no peripheral source of antigen existed.  Peripheral CD4 T cells or 
thymocytes from athyroid animals were transferred into thyroiditis-prone 
hosts.  Whereas thymocytes from athyroid animals were able to function 
effectively as regulatory T cells and prevent thyroiditis, peripheral CD4 T 
cells from athyroid animals were ineffective suppressors and could not 
inhibit the development of autoimmunity.  Peripheral CD4 T cells were 
presumably ineffective due to their lack of exposure to antigen in the 
periphery in athyroid animals.  In addition, the ineffectiveness of 
peripheral CD4 T cells proved to be antigen-specific, as these cells were 
able to prevent the development of other forms of autoimmunity such as 
diabetes.  
 
There are various pathways that lead to the production of regulatory T 
cells in the periphery from effector or memory CD4 T cells.  Tr1 cells are 
a type of adaptive regulatory T cell, defined by their dependence on IL-10 
(Roncarolo, Gregori et al. 2006).   IL-10 is required for the induction of 
Tr1 cells in vivo, and is responsible, in part, for Tr1-mediated 
suppression.  Suppression by Tr1 cells is carried out by secretion of the 
anti-inflammatory cytokines IL-10 and TGF-β.  IL-10 was initially 
discovered by its ability to block cytokine secretion from Th1 cells 
(Moore, Vieira et al. 1990).  Its immunosuppressive properties have been 
extended to include down regulation of costimulatory molecules and 
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inhibition of pro-inflammatory cytokine production by APCs (Roncarolo, 
Gregori et al. 2006).  TGF-β acts to inhibit proliferation and 
differentiation of both CD4 and CD8 T cells (Li, Wan et al. 2006).  
Adaptive regulatory T cells, in addition to natural regulatory T cells, have 
been shown to play a role in preventing autoimmunity.    Defects in Tr1 
cells have recently been discovered in patients with multiple sclerosis 
(MS) (Astier, Meiffren et al. 2006).   MS is an autoimmune disease 
characterized by inflammation in the CNS and destruction of myelin.  Tr1 
cells from MS patients were hyporesponsive to stimulation in vitro and 
secreted lower levels of IL-10 compared to Tr1 cells from healthy donors 
(Astier, Meiffren et al. 2006).   
 
The immune system is responsible for protecting the body from foreign 
invaders.  It is therefore essential that the immune repertoire be armed 
with receptors capable of identifying any foreign substance or organism.  
To ensure a sufficient amount of diversity among lymphocytes, the 
immune system randomly arranges receptors to create a repertoire that 
consists of billions of different clones.  Given the randomness and 
magnitude of lymphocyte diversity, a portion of the immune system will 
unavoidably be able to recognize self-tissue.  Tolerance is therefore 
essential to protect the body from its own defenses.  Maintaining 
immunologic tolerance is tantamount to generating effective immune 
responses against foreign pathogens.   The multiple, and sometimes 
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redundant mechanisms behind tolerance induction reflect the 
importance of preventing self-reactivity.  Anti-Hu syndrome offers a 
unique opportunity to study tolerance to a self-protein expressed 
exclusively in neurons.  The fact that all SCLCs express the HuD protein, 
but only 15% of SCLC patients mount a detectable immune response to 
HuD, suggests that the immune system is normally tolerized to HuD, 
and that tolerance is broken in patients with anti-Hu antibodies.   Of the 
15% of patients with anti-Hu antibodies, a very small population goes on 
to develop neuronal autoimmunity.   This implies an additional 
requirement besides the loss of tolerance to HuD for the generation of 
brain disease.    The uniqueness of the central nervous system, and the 
properties that distinguish it from other tissues in the body, undoubtedly 
contribute to the rare incidences of autoimmune mediated neuronal 
degeneration.  
 
Immunosurveillance and inflammation of the central nervous 
system 
The CNS has historically been considered an immune privileged site.  
Immune privilege signifies the inability of the immune system to access 
and survey certain anatomical sites.   Surveillance of the CNS was 
considered impractical due to a lack of lymphatic drainage from the CNS 
parenchyma, the absence of traditional antigen presenting cells (APCs), 
and the presence of the blood-brain barrier (Ransohoff, Kivisakk et al. 
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2003).  These factors represented physical and functional barriers that 
combined to make the CNS unreachable by the immune system.   We 
now understand that the immune system is not excluded from the CNS, 
although access is more carefully monitored relative to other tissues.  
 
The blood-brain barrier 
The CNS consists of the brain and spinal cord, covered by three layers of 
membrane and encased in bone.   Cerebrospinal fluid (CSF) is generated 
locally by specialized secretory cells of the choroids plexuses, which are 
located within individual ventricles, or cavities, of the brain.  After 
formation in the ventricles, CSF circulates through the brain and spinal 
cord before being reabsorbed into venous blood.   Recent studies indicate 
that CSF also drains into cervical lymph nodes, making it a unique form 
of lymph specific to the CNS (de Vos, van Meurs et al. 2002; Karman, 
Ling et al. 2004).   The extracellular fluid that bathes the parenchyma of 
the brain has access to CSF so that soluble proteins from CNS grey and 
white matter can readily reach lymphoid tissues (Ransohoff, Kivisakk et 
al. 2003).    Evidence of CSF flow into cervical lymphatics makes it clear 
that there is appreciable immune surveillance of soluble CNS antigens.  
 
Movement of cells into the CNS is a tightly regulated process.  Capillaries 
of the CNS vasculature protect the parenchyma by excluding circulating 
cells and macromolecules on account of endothelial tight junctions.  
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Tight junctions seal the gap between the blood and CNS, preventing 
movement of lymphocytes across the endothelium.  Movement of solutes 
is also precluded by the inability of endothelial cells to pinocytose.  
Together, these unique features of the endothelium are referred to as the 
blood-brain barrier.   In a healthy state, the blood-brain barrier is an 
effective impediment to lymphocyte migration across the CNS 
endothelium.  However, experimental evidence indicates that 
lymphocytes are able to gain access to the CNS under inflammatory 
conditions (Hickey 2001).   TNFα is a proinflammatory cytokine that 
causes marked changes in the blood-brain barrier when produced either 
locally or systemically (Hickey 2001).  In both in vitro and in vivo models, 
TNFα has been shown to increase the permeability of the blood-brain 
barrier, thereby enhancing the passage of material between the blood 
and CNS (Mark and Miller 1999) (Dickstein, Moldofsky et al. 2000).   
Other proinflammatory substances such as LPS and IFNγ influence the 
permeability of the blood-brain barrier by activating endothelial cells of 
the CNS vasculature, resulting in upregulation of adhesion molecule 
expression (Hickey 2001).    
 
Inflammation in the CNS 
Although the CNS is normally protected from the development of harmful 
immune responses, inflammatory reactions can occur behind the blood-
brain barrier. Whereas naïve lymphocytes are rarely found in the 
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parenchyma of the brain, activated T cells readily traverse the CNS 
regardless of antigen specificity (Karpus and Ransohoff 1998; Becher, 
Bechmann et al. 2006).   Antigen specificity becomes important for 
retention of T cells behind the blood-brain barrier and the subsequent 
initiation of an inflammatory immune response.   Inflammation requires 
antigen-specific stimulation of activated T cells that have crossed into the 
brain, which in turns depends on the presence of an antigen presenting 
cell (APC) in the CNS (Becher, Bechmann et al. 2006) (Perry 2004).    
Antigen-specific stimulation of T cells in the CNS is a complicated 
process given the multiplicity of APCs with the potential to function as T 
cell stimulators.  There are both endogenous and peripheral APCs 
present in the inflamed CNS.   Peripheral macrophages and DCs are 
recruited as part of the inflammatory response whereas microglia are 
resident APCs with the capacity to express MHC and costimulatory 
molecules.  In a normal, nonpathologic state, microglia express 
insufficient levels of MHC molecules and are therefore incapable of 
functioning as APCs (Aloisi 2001).  MHC expression is quickly 
upregulated under inflammatory or neurodegenerative conditions so that 
microglia become important participants in the CNS immune response 
(Aloisi 2001; Carson, Doose et al. 2006).  Despite their role in the 
development of CNS inflammation, microglia do not appear to be the cell 
type responsible for initiating T cell responses behind the blood-brain 
barrier.  Rather, peripheral DCs are sufficient for the induction of CNS 
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inflammation (Carson, Doose et al. 2006) (Lauterbach, Zuniga et al. 
2006) (Greter, Heppner et al. 2005).    The prevailing model for the 
generation of CNS pathology begins with the induction of an 
inflammatory response as a result of CNS antigen-specific T cell 
stimulation by peripheral DCs behind the blood-brain barrier, followed 
by infiltration of mononuclear cells and additional T cells into the CNS 
parenchyma where microglia are able to direct T cell effector function 
(Ransohoff, Kivisakk et al. 2003; Carson, Doose et al. 2006).   
 
Experimental autoimmune encephalomyelitis 
The most commonly studied example of CNS inflammation is 
experimentally induced autoimmune encephalomyelitis (EAE).  EAE is a 
mouse model of multiple sclerosis (MS) characterized by autoimmunity 
directed against components of the myelin sheath.  Disease is commonly 
mediated by myelin-specific CD4 T cells that have infiltrated the CNS 
(Becher, Bechmann et al. 2006).    To generate EAE, mice are immunized 
with myelin peptides or proteins (most commonly MOG, PLP or MBP) in 
order to prime myelin-specific CD4 T cells in the periphery.  The 
pathology is initiated when activated myelin-specific T cells traffic to the 
CNS and induce inflammation, characterized by peripheral APC 
recruitment to the brain and spinal cord, upregulation of MHC and 
costimulatory molecules on resident microglia, and eventual 
demyelination (Becher, Bechmann et al. 2006).   Peripheral APCs that 
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have been recruited to the CNS are necessary and sufficient to stimulate 
activated myelin-specific CD4 T cells behind the blood-brain barrier 
(Greter, Heppner et al. 2005).   Although microglia do not seem to play a 
role in the initiation of CNS inflammation, they participate in the ongoing 
inflammatory reaction by modifying T-cell effector function within the 
parenchyma (Carson, Doose et al. 2006).   Using irradiation bone marrow 
chimeras, it was shown that expression of CD40 on microglia is 
necessary for the exacerbation of EAE (Becher, Durell et al. 2001).   
Microglia are capable of phagocytosing antigen when activated under 
inflammatory conditions, and experimental evidence suggests that 
processing and presentation of myelin epitopes to infiltrating T cells by 
resident microglia is important for the progression of CNS disease 
(Prineas, Kwon et al. 2001) (Carson 2002).   
 
Immunosuppression in the CNS 
Inflammatory responses in the CNS can cause irreparable damage, as 
evidenced by autoimmune diseases like EAE and PND.   In order to 
prevent immune-mediate neurodegeneration, the CNS has designed ways 
to mitigate immune responses behind the blood-brain barrier.   
Regulation of infiltrating lymphocytes by resident brain cells is an active 
process designed to limit or suppress CNS inflammation.    Constitutive 
expression of FasL in the CNS promotes apoptosis of activated T cells, 
and immunosuppressive cytokines, most notably TGF-β, act to inhibit 
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inflammation (Bechmann, Mor et al. 1999; Vitkovic, Maeda et al. 2001).  
Microglia have the capacity to promote inflammation and tissue damage 
in some circumstances, but also function to preserve homeostasis in the 
CNS (Minghetti and Levi 1998; Streit 2002).    Neuroprotection is 
demonstrated by the role of microglia in the regeneration of motor 
neuron axons after facial nerve axotomy (Streit 2002).   Facial nerve 
axotomy involves transecting or severing the axons of the facial nerve, 
and is a widely used model of degeneration and regeneration of the 
nervous system in vivo (Moran and Graeber 2004).   There is effective 
communication between neurons and microglia, as evidenced by the 
activation of microglia within the CNS subsequent to transection of 
axons in the periphery (Streit 2002) (Bessis, Bechade et al. 2007).   
Activated, phagocytic microglia surround dying neurons and neuronal 
debris, and following axotomy, function to remove synaptic terminals 
from the cell body, a process that has been termed “synaptic stripping” 
(Moran and Graeber 2004) (Raivich, Jones et al. 1998).    The activation, 
proliferation and ensheathment of neurons by microglia in response to 
neuronal injury are vital to the regeneration of motor axons, and 
highlight the role of microglia as neuroprotective cells in the CNS.     
 
CD8 T cell mediated disease in the CNS 
The apparent interactions between microglia and neurons reflect a 
dynamic CNS environment that promotes communication amongst 
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resident cells.    For antigen-specific T cell mediated neurodegeneration, 
there is a requirement for contact between neurons and infiltrating T 
cells.  In our model of anti-Hu syndrome, disease pathogenesis depends 
on the targeting of HuD expressing neurons by activated HuD-specific 
CD8 T cells.  This in turn requires MHC I expression on neurons, which 
then serve as targets for CD8 T cells.  Whereas peripheral tissues readily 
express MHC I molecules in order to guard against intracellular infection, 
healthy neurons have undetectable surface expression of MHC I, 
supporting the perception of the CNS as an immune privileged site.  
Under pathologic conditions, however, when the CNS environment 
switches from being immunosuppressive to inflammatory, neurons 
upregulate MHC I expression.   Upregulation of MHC I is achieved by 
silencing electrical activity in combination with exposure to pro-
inflammatory cytokines, most notably IFNγ (Neumann, Cavalie et al. 
1995; Neumann, Schmidt et al. 1997).    After induction of MHC I 
expression, neurons are susceptible to antigen-specific lysis by activated 
CD8 T cells (Medana, Gallimore et al. 2000).  CD8 T cells can kill 
neurons by perforin-induced pore formation or through induction of 
apoptosis by Fas ligand (Rensing-Ehl, Malipiero et al. 1996; Medana, 
Gallimore et al. 2000).   Studies of CD8-mediated neuronal death have 
relied on in vitro systems, using cultured neurons treated with cytokines 
or chemicals to induce MHC I expression.   There is still a need for 
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conclusive evidence of CD8 T cell mediated killing of neurons in vivo, 
under pathologic conditions.   
 
EAE is generally considered a CD4 T cell mediated illness, since adoptive 
transfer of myelin-specific CD4 T cells is sufficient to induce disease in 
naïve animals. However, CD8 T cells are equally capable of initiating 
autoimmune demyelination.  Demyelination can be generated by CD8 T 
cells specific for myelin basic protein (MBP), and depends on the 
production of the inflammatory cytokine IFNγ (Huseby, Liggitt et al. 
2001).  Adoptively transferred MBP-specific CD8 T cells are able to traffic 
to the CNS and induce autoimmune neurologic disease in recipient 
animals.  Evidence from studies of MS patients supports the idea that 
CD8 T cells play an important role in autoimmune demyelination (Ji and 
Goverman 2007).  CD8 T cells outnumber CD4 T cells by nearly ten-fold 
in MS brains (Booss, Esiri et al. 1983).   In addition, CD8 T cells specific 
for a protein expressed in oligodendrocytes were detected in the blood of 
patients with MS but not control subjects (Niland, Banki et al. 2005).   
These T cells were shown to lyse oligodendrocytes expressing the 
appropriate MHC I allele in vitro, which suggests a possible mechanisms 
for CD8 T cell mediated demyelination in patients.    
 
CD8 T cell mediated neurologic disease occurs spontaneously in 
transgenic mice with constitutive expression of the costimulatory 
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molecule B7.2/CD86 on microglia (Zehntner, Brisebois et al. 2003; 
Brisebois, Zehntner et al. 2006).    Expression of B7.2/CD86 on resident 
CNS microglia creates a permanent immunostimulatory environment for 
infiltrating T cells that naturally leads to the development of 
autoimmunity, highlighting the importance of inflammation behind the 
blood-brain barrier to the generation of CNS autoimmune disease.   In 
this model, CD8 T cells are the effector cells responsible for disease 
pathogenesis, whereas CD4 T cells play an inhibitory role in disease 
development.   In the absence of CD4 T cells, B7.2 transgenic mice 
succumb to neurologic disease more rapidly, suggesting a protective role 
for CD4 T cells in the activation of myelin-specific CD8 T cells (Brisebois, 
Zehntner et al. 2006).    Regulatory CD4 T cells may help to suppress 
CD8 T cells specific for CNS self-antigens, so that depletion of the CD4 T 
cell repertoire in the B7.2 transgenic model serves to eliminate this 
important inhibitory population, resulting in accelerated disease.   
 
Regulatory T cells in the CNS 
It is unclear how regulatory T cells react to inflammation in the CNS.  
Pathologic inflammatory responses behind the blood brain barrier are 
apparently able to overcome immune suppression induced by regulatory 
T cells.  With regard to designing better therapeutic approaches, it is 
important to determine whether regulatory T cells fail to traffic to the 
target organ altogether, or if their mode of suppression is inhibited in the 
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midst of an inflammatory response.   In mice that were immunized with 
MOG to induce EAE, it was found that regulatory T cells persisted in the 
CNS during the course of disease but were unable to prevent 
demyelination by MOG-specific effector CD4 T cells (Korn, Reddy et al. 
2007).  Regulatory T cells from the inflamed CNS effectively blocked 
proliferation of effector CD4 T cells isolated from the spleen but could not 
suppress proliferation of CNS effector T cells.    These results suggest 
that during EAE, regulatory T cells in the periphery are functional 
suppressors that traffic to the target organ.  Once inside the inflamed 
CNS, however, these cells are incapable of preventing autoimmune 
mediated demyelination.    The failure on the part of CNS regulatory T 
cells to suppress disease seemed to be due, in part, to the cytokine 
milieu.   Effector CD4 T cells isolated from the CNS secreted large 
amounts of pro-inflammatory cytokines, namely IL-6 and TNFα (Korn, 
Reddy et al. 2007).   When peripheral regulatory T cells were exposed to 
these two cytokines in vitro, their suppressive effect was abrogated.     
This suggests that regulatory T cells in the inflamed CNS are ineffective 
at limiting autoimmunity due to the production of pro-inflammatory 
cytokines by effector cells within the target organ.    
 
Inhibition of regulatory T cells within the inflamed CNS during EAE can 
happen as a result of the local cytokine environment (Korn, Reddy et al. 
2007).    Pro-inflammatory cytokines function to reverse the suppressive 
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properties of regulatory T cells and allow for the escalation of an effective 
immune response behind the blood brain barrier.   Normally, the brain is 
bathed in TGF-β, a potent anti-inflammatory cytokine.  TGF-β acts to 
maintain tolerance through regulation of lymphocyte proliferation and 
survival, but it can also drive the differentiation of CD4 T cells into 
regulatory T cells (Li, Wan et al. 2006).    Differentiation of CD4 T cells 
into regulatory T cells via TGF-β is inhibited when inflammatory 
cytokines, namely IL-6, are present.  In the presence of both IL-6 and 
TGF-β, CD4 T cells differentiate into Th17 cells (Veldhoen, Hocking et al. 
2006) (Bettelli, Carrier et al. 2006).   Th17 cells contribute to many 
inflammatory immune responses, and have been implicated in the 
development of autoimmunity (Kikly, Liu et al. 2006).    Regulatory T cell 
development and Th17 differentiation were shown to be mutually 
exclusive pathways for naïve CD4 T cells (Bettelli, Carrier et al. 2006).    
The presence of IL-6, and perhaps other inflammatory cytokines, is 
therefore critical to shaping the CD4 T cell immune response.   Exposure 
to inflammatory cytokines in the CNS, where there is constitutive 
expression of TGF-β, would serve to promote the development of effector 






Tolerance to CNS antigens  
The CNS is considered an immune privileged site due to the presence of 
the blood-brain barrier, which is designed to limit or restrain the 
initiation of inflammatory immune responses.   Inflammation of the CNS 
does occur, necessitating protection from autoimmunity via tolerance 
induction to CNS antigens.  CNS proteins are not hidden or ignored by 
the immune compartment, and therefore mechanisms must exist to 
safeguard against autoimmune neurologic disease.   Experimental 
evidence of tolerance to CNS antigens has focused on the myelin 
proteins, since EAE is the most prevalent model of CNS autoimmunity.   
EAE is induced by priming T cells to myelin self-antigens, such as myelin 
oligodendrocyte glycoprotein (MOG), proteolipid protein (PLP), and myelin 
basic protein (MBP).  All three proteins are components of myelin, but 
tolerance to each is maintained in different ways.   
 
Tolerance to the myelin proteins 
Central tolerance ensures that PLP-specific T cells do not escape from the 
thymus.   Thymic expression is restricted to a shorter splice variant of 
PLP called DM20, so that T cells specific for epitopes within DM20 are 
deleted during development.   C57BL/6 mice are resistant to PLP-
induced EAE because DM20 expression in the thymus is sufficient for 
the elimination of PLP-specific clones.   SJL/J mice, conversely, are 
highly susceptible to PLP-induced EAE since PLP-specific CD8 T cells in 
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this strain respond to an epitope not found in DM20 and are not deleted 
during development (Anderson, Nicholson et al. 2000; Klein, Klugmann 
et al. 2000).   
 
MOG is a minor component of CNS myelin, distinguished from other 
myelin autoantigens by its immunodominance.  Tolerance to MOG is 
weak, despite the generation of MOG-specific regulatory T cells in the 
thymus (Korn, Reddy et al. 2007).  The frequency of MOG-specific 
natural regulatory T cells is so low that these cells are unable to 
suppress the activation of an immune response to MOG upon 
immunization (Delarasse, Daubas et al. 2003; Korn, Reddy et al. 2007).   
MOG-deficient animals mount an immune response to the protein that is 
identical to that of their wild type counterparts, and MOG-specific T cells 
from either wild type or MOG-deficient mice induce comparable disease 
upon adoptive transfer (Delarasse, Daubas et al. 2003).  
 
Tolerance to MBP happens both in the thymus and in the periphery.  
Thymic expression is limited to a non-classical form of MBP (called golli-
MBP) that contains stretches of sequence identical to peripheral MBP 
(Tranquill, Skinner et al. 1996; Cabbage, Huseby et al. 2007).   Because 
certain epitopes of classic-MBP are missing, tolerance is also mediated by 
thymic APCs that have acquired MBP from the periphery (Huseby, Sather 
et al. 2001).  Tolerance to MBP has been studied with regard to MBP-
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specific CD4 and CD8 T cells.  CD4 T cells specific for an immunogenic 
epitope not found in golli-MBP (MBP121-140) are deleted during 
development through cross presentation of exogenous MBP by thymic 
APCs (Huseby, Sather et al. 2001).   Negative selection does not 
completely eliminate MBP-specific CD4 T cells from the repertoire, 
however, due to developmentally regulated expression of MBP in the 
periphery.  In young mice (< 3 weeks old), a population of MBP-specific 
CD4 T cells escapes thymic selection as a result of low levels of MBP 
protein expression during the first 2 to 3 weeks of life (Huseby, Sather et 
al. 2001).   In order to keep these self-reactive T cells in check, MBP-
specific CD4 T cells are suppressed in the periphery by regulatory T cells 
(Cabbage, Huseby et al. 2007).  
 
Pathogenic MBP-specific CD8 T cells that recognize an epitope contained 
within golli-MBP (MBP79-87) are also tolerized (Huseby, Ohlen et al. 1999; 
Perchellet, Stromnes et al. 2004).  To study the mechanisms behind 
tolerance induction of MBP-specific CD8 T cells, two distinct T cell 
receptor (TCR) transgenic mice were created, both with specificity for 
MBP79-87. Despite their inherent similarities, these two T cell populations 
were subject to very different forms of tolerance induction.   CD8 T cells 
from one mouse were subject to central and peripheral tolerance 
induction.    The majority of these cells were deleted in the thymus 
during development, and those that escaped were inactivated in the 
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periphery.   CD8 T cells from the second TCR transgenic mouse bypassed 
both forms of tolerance, as there was no deletion in either the thymus or 
periphery.  The most striking observation was the capacity of this second 
T cell line to rescue other MBP-specific CD8 T cells from tolerance 
induction.  Based on their experimental results, the authors purpose a 
model whereby certain MBP-specific CD8 T cells are able to strip APCs of 
MBP peptide as a means of inducing tolerance (Perchellet, Stromnes et 
al. 2004).    
 
Tolerance to neuronal proteins? 
Tolerance to myelin antigens is maintained by a variety of mechanisms, 
and understanding how the immune system responds to myelin epitopes 
is of great clinical significance with regard to designing better therapies 
for the treatment of MS.   HuD is similar to the myelin proteins in that it 
is specific to the nervous system.  Unlike the myelin proteins, HuD is an 
intracellular protein expressed exclusively by neurons.  To date, there is 
no evidence of tolerance to neuronal antigens.   The recognition of Hu-
expressing neurons by autoreactive T cells appears to be responsible for 
neuronal degeneration in patients with the Hu syndrome.  Since all 
SCLCs express the HuD antigen but only a fraction of patients mount a 
detectable immune response to the protein, there are apparent 
mechanisms responsible for preventing autoimmunity directed against 
this antigen.  Immune privilege to HuD could potentially occur through 
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deletion of HuD-specific T cells from the repertoire.   If this were true, 
patients with HuD-specific immune responses would necessarily avoid 
central tolerance induction.  Alternatively, HuD-specific T cells that 
circulate in the periphery may be ignorant of the protein, given the lack 
of neuronal MHC expression under non-inflammatory conditions. 
Reliance on immunologic ignorance is risky, however, as neurons are 
able to upregulate MHC I expression during inflammation at the same 
time as activated T cells are allowed entry to the CNS.   If HuD-specific T 
cells avoid thymic deletion, suppression in the periphery via regulatory T 
cells or anergy induction may serve to prevent the development of 
neuronal autoimmunity.  To date, there is no evidence of tolerance to 




Patients with the Hu syndrome mount an immune response to HuD that 
is evidenced by the presence of high titer antibodies to the protein in the 
blood and CSF.  Hu patients have impressive tumor immunity coupled 
with severe neurologic disease, presumably mediated by HuD-specific T 
cells that are able to target both tumor cells and neurons expressing the 
Hu antigen.  
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CD8 T cells are designed to monitor the intracellular compartment.  
Given the intracellular location of the HuD antigen, HuD-specific CD8 T 
cells are expected to be responsible for recognition and destruction of 
HuD expressing cells in patients with the Hu syndrome. To better 
understand the mechanisms behind CD8 T cell mediated 
neurodegeneration, we sought to generate a mouse model of disease.   An 
exhaustive screen of the entire HuD peptide library was performed in 
C57BL/6 in order to identify immunogenic epitopes of the HuD protein.    
Potential epitopes were then assessed for their ability to be naturally 
processed and presented by the immune system, which allowed for the 
identification of the immunodominant CD8 T cell epitope of HuD.   HuD-
specific CD8 T cells were subjected to phenotypic and functional assays 
in order to determine if these cells behave as typical cytotoxic T cells 
capable of lysing HuD expressing targets.    In order to understand how 
HuD-specific CD8 T cells mediate neurodegeneration, we established an 
adoptive transfer model that enabled us to study HuD-specific CD8 T cell 
trafficking to the CNS.  
 
Maintaining tolerance is critical to protecting the body from destructive 
immune responses against self-antigens.  Studies on the mechanisms 
behind tolerance induction have focused primarily on peripheral 
antigens. How the body maintains tolerance to neuronal proteins is 
poorly understood.  To better understand this process, we sought to 
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investigate tolerance induction to HuD.  We also compared tolerance to 
HuD versus its related family member HuA.   HuA shares high sequence 
homology with HuD, however the protein is not neuron-specific but 
ubiquitously expressed.  The difference in expression between HuD and 
HuA suggested that the two proteins might be subjected to different 
forms of tolerance induction.  We hypothesized that tolerance to HuA 
would be stricter compared to HuD since the protein is present in all 
tissues and not restricted in expression to neurons.   
 
Finally, we sought to identify clinically relevant human HuD epitopes in 
order to better understand and diagnose anti-Hu syndrome.   Prior to 
this study, no definitive proof of the presence of HuD-specific CD8 T cells 
in patients with the Hu syndrome existed.  In order to determine if HuD-
specific CD8 T cells are expanded and activated during disease 
pathogenesis, we sought to identify human immunogenic CD8 T cell 
epitopes of HuD.   A comprehensive screen of the entire HuD peptide 
library was performed over 8 human HLA MHC I alleles.    In this way, 
two human CD8 T cell epitopes of HuD were discovered.   Based on these 
results, we designed HuD-specific tetramers in order to identify and 





CHAPTER II. MATIERALS AND METHODS 
 
Peptides. 
The peptide library for iTopia screening was purchased from Jerini 
Peptide Technologies (Berlin, Germany).  All other peptides were 
purchased from American Peptide Company.   
 
Mice.   
Wild type C57BL/6, Thy1.1 (stock no. 000406), and Rag1-/- (stock no. 
00216) mice were purchased from The Jackson Laboratory.  HuD-/- mice 
were obtained from H. Okano (ref PNAS paper).  A2.1 transgenic HHD 
mice were provided by Dr. Francois Lemonnier (Pasteur Institute).  A2.1 
transgenic AAD mice were purchased from The Jackson Laboratory.    
AIRE mice were purchased from The Jackson Laboratory (stock no. 
004743).   
 
HuD Peptide Screen. 
C57BL/6 mice were injected in the right footpad with a single HuD 
peptide emulsified in Titermax adjuvant.  To form the peptide emulsion, 
75ul of HuD peptide at 10mg/mL in 50% DMSO was added to 75ul 
ddH20.  This solution was then added to a sterile eppendorf tube 
containing 150ul Titermax adjuvant.  The tube was then vortexed for 30 
minutes on high to form an emulsion.  The emulsion was drawn into an 
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insulin syringe and 50ul (approximately 125ug of peptide) was injected 
per animal.  After 7 days, the animal was sacrificed and the right 
popliteal and inguinal lymph nodes were removed. Lymph nodes were 
ground between two sterile frosted glass slides to obtain a single cell 
suspension.  CD8 T cells were isolated by MACS purification (Miltenyi 
Biotec) and plated in a 20 hour IFNγ ELISPOT assay at 2 x 105 CD8 T 
cells per well.   EL4 cells were added as stimulators at 5 x 104 per well 
with 10uM peptide.    
 
Immunizations. 
For immunization with recombinant adenovirus, 6-8 wk old mice were 
injected with 100ul purified adenovirus (109 PFU/mL) i.d. and treated 
with Pertussis Toxin (Sigma) at days 0 and 2.    
For EAE induction, 6-8 wk old C57BL/6 mice were immunized with 
100ug MOG35-55 in CFA and treated with Pertussis Toxin on days 0 and 
2.   
 
Preparation of cells from the brain.   
Brains were removed from mice perfused with 50 mL cold heparinized 
saline and mechanically dissociated using a dounce homogenizer (VWR) 
in HBSS w/ Ca and Mg (Gibco) containing 500ug/mL Collagenase D 
(Roche), 5mg/mL Dispase II (Roche), 20U/mL DNase I (Roche) and 10mM 
HEPES (Gibco).   The dissociated tissue in solution was incubated for 15 
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minutes on a rotating neutator and then left to stand for an additional 15 
minutes.   The resulting cell suspension was washed once in R-10 media 
(RPMI 1640 supplemented with 10% FBS, nonessential amino acids, 
sodium pyruvate, glutamine, 22-ME, gentamicin) and fractionated on a 
30/37/70% percoll gradient at 1760rpm for 30 minutes.  Cells were 
collected from the 37/70% interface.    
 
Preparation of primary murine kidney cells.  
Kidneys from adult mice were mashed using the back of a syringe and 
pipetted until a single cell suspension was obtained.  The cell suspension 
was passed over a 70um cell strainer and washed in D-10 (DMEM 
supplemented with 10% FBS, nonessential amino acids, sodium 
pyruvate, glutamine, 22-ME, gentamicin) before plating in 10cm dishes.  
Cultures were fed by replacing D-10 on days 4 and 7.  On day 7, 
recombinant mouse IFNγ (R & D Systems) was added at 10U/mL.  On 
day 8, 10ul recombinant adenovirus at 109 PFU/mL was added to each 
dish and the cells were harvested on day 9 for use in an IFNγ ELISPOT 
assay.   
 
Adenovirus production. 
Recombinant adenoviruses expressing GFP, β-galactosidase, or HuD-GFP 
was made by H. Okano.  Recombinant adenovirus expressing HuA-GFP 
was made by inserting the full-length HuA gene into the pAdenoTrack 
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vector as previously described (He, PNAS 1998).  Virus was produced by 
transduction of HEK293 cells (ATCC) and purified using the Adenopure 
Kit (Puresyn) according to the manufacturer’s instructions.  Viral titers 
were assessed by infection of HEK293 cells with serial dilutions of 
purified virus followed by determination of the number of virally infected 
cells after 20 hours by fluorescence or XGal staining.   
 
Retrovirus production. 
Retrovirus was produced by transfection of ecotropic Phoenix cells (a gift 
from the DeLange Lab, Rockefeller University) with retroviral constructs 
containing either HuD-GFP or GFP.  48 hours post transfection, viral 
supernatant was harvested and used directly to infect target cells.  10mL 
viral supernatant was added per 10cm dish of targets with polybrene 
(5mg/mL).   
 
Elispot assay.  
CD8 cells were isolated from spleens or lymph nodes of immunized mice 
using MACS purification (Miltenyi Biotec).   T cells were added to IFNγ 
ELISPOT plates at the indicated concentrations along with stimulators 
and incubated for 20.  Cells were washed out of the ELISPOT plate using 
a mild detergent followed by incubation with 1ug/mL biotin-conjugated 
anti-IFNγ mAb.  Wells were developed using the Vectastain Elite Kit 
according to the manufacturer’s instructions (Vector Laboratories).  
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Colored spots represent IFNγ-secreting cells and are enumerated as spot 
forming cells (SFCs) per 106 cells.  The ELISPOT plate evaluation was 
performed by an independent evaluation service (Zellnet Consulting) 
using an automated ELISPOT reader (Carl Zeiss).   
 
Mouse dendritic cell preparation. 
Bone marrow-derived DCs were prepared as previously described (Inaba 
1992 JEM).  Briefly, bone marrow from tibia and femurs was lysed of 
RBC and cultured in 6 well plates in R-10 in the presence of GM-CSF (ref 
for J558L).  Fresh GM-CSF supplemented medium was added to the 
wells on days 2, 4, and 6.  On day 7, DCs were matured for 2 days with 
recombinant mouse TNFα (R&D Systems) by harvesting and re-plating at 
106/mL in 6 well plates with GM-CSF supplemented medium plus 
recombinant mouse TNFα (125ng/mL).    
 
Mouse antibody titers. 
Sera from mice were diluted in 5% Dry Carnation Milk (Carnation Co.) in 
.1% Tween/PBS and incubated with PVDF membrane strips containing 
identical amounts of recombinant HuD antigen.  The membrane was 
then washed thoroughly in .1%Tween/PBS and incubated with 
horseradish peroxidase-conjugated secondary antibody.  Signal was 
visualized with a chemiluminescent substrate and a 35kD band 
indicated the presence of anti-HuD antibody.   
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Western blot with cell lysates.  
106 cells were lysed in 100ul of passive lysis buffer (Promega).  25ul of 
lysate (or 1ug rHuD) was run on a 10% SDS-polyacrilamide gel and 
transferred to a PVDF membrane.   The membrane was blocked in 5% 
Dry Carnation Milk (Carnation Co.) and incubated with Anti-Hu patient 
sera (at 1:1000). The membrane was then washed thoroughly in 
.1%Tween/PBS and incubated with horseradish peroxidase-conjugated 
secondary antibody.  Signal was visualized with a chemiluminescent 
substrate and a 35kD band indicated the presence of HuD protein.  
 
Mouse CD8 T cell stimulations. 
For in vitro stimulation, 2.5-3 x 107 splenocytes from adenovirus-
immunized mice were incubated at 37°C in upright T25 culture flasks 
(Corning) in R-10 (half of a spleen per flask) with .5uM peptide for 7 
days.  For further rounds of restimulation, splenocytes were plated in 24 
well plates (2-6 x105 splenocytes per well) with peptide-pulsed feeder 
cells in R-10 with 50 CU/mL recombinant human IL-2 (Chiron).  Feeder 
cells were prepared from spleens of naïve syngeneic mice by pulsing with 
.5uM peptide for 1 hour at room temperature and irradiating at 3,000 





Adoptive transfer.  
For adoptive transfer experiments, mice received i.v. injections of in vitro 
stimulated CD8 T cells (5 x 106 CD8/mouse) and DCs pulsed with 
peptide (2 x 106 DC/mouse) along with IL-2 (6 injections of 105 
CU/mouse i.p. every 12 hours) and Pertussis Toxin (400ng/mouse i.p. 
on days 0 and 2). In vitro stimulation of CD8s was performed as 
described.  After 7 days of stimulation, CD8s were isolated by negative 
selection using a CD8 T cell isolation kit (Miltenyi Biotec).  The cells were 
washed twice and resuspended at 2.5 x 107/mL in RPMI 1640DCs for i.v. 
injection. DCs were prepared from bone marrow as described.  For the 
peptide pulse, TNFα-matured DCs were resuspended at 107 DCs/mL in 
R-10 with 100uM peptide and incubated at room temperature for 1 hour, 
shaking every 15 minutes.  The cells were then washed twice and 
resuspended at 107/mL in RPMI 1640 for i.v. injection.     
 
In Vivo CTL assay. 
Mice received a single i.v. injection of target cells.  The targets consisted 
of two populations of cells in a 1:1 ratio:  irrelevant peptide-pulsed 
syngeneic splenocytes labeled with .5uM CFSE (CFSElo) and relevant 
peptide-pulsed syngeneic splenocytes labeled with 5uM CFSE (CFSEhi).   
To prepare target cells, spleens from syngeneic mice were mashed with 
the back of a syringe, decanted into two 15mL conical tubes, and 
pelleted.  To lyse erythrocytes, each pellet was resuspended in 5mL ACK 
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lysis buffer (Gibco) and left at room temperature for 4 minutes.  Lysis 
was stopped by adding 8mL cold PBS to each tube.  The cell suspensions 
were combined in a 50mL conical tube, pelleted, resuspended in 10mL 
warm R-10 and passed through a 70um cell strainer.  To pulse with 
peptide, the cells were divided into two equal populations at a final 
concentration of 107/mL in R-10.   One population was pulsed with 
10uM cognate peptide and the other with 10uM irrelevant peptide at 
37°C for 90 minutes, shaking every 15 minutes.   After 90 minutes, 
excess peptide was removed by washing the cells three times in PBS.  
The last wash was done in room temperature PBS.  Cells were counted 
and resuspended at 5 x 107 in warm (37°C) PBS. The irrelevant peptide-
pulsed population was labeled with .5uM CFSE (CFSElo) and the relevant 
peptide-pulsed population with 5uM CFSE (CFSEhi).   To label the cells, 
CFSE was added to the tubes, which were then inverted 6 times and 
placed at 37°C for 10 minutes.   Labeling was stopped by adding ice cold 
PBS to the tubes.  The cells were washed once in cold PBS, and then 
twice in room temperature PBS.  The cells were resuspended at 108/mL 
and combined in a 1:1 ratio.  Mice received a single i.v. injection of 200ul 
(107 CFSElo and 107 CFSEhi targets).  5-18 hours after target injection, 
the spleens were removed and the amount of CFSElo versus CFSEhi 




Flow cytometry.  
All surface antibodies were purchased from Beckton Dickinson.  106 cells 
were resuspended in 100ul staining buffer (PBS containing 1% pooled 
human serum, 1% FBS and 5% goat serum) and Fc blocked for 10 
minutes using 1ug of anti-CD16/CD32 (FcγR11/III).  1ug of each specific 
Ab was added directly to the cells and incubated for 15 minutes at 4°C.  
Cells were then washed twice and analyzed using a BD FACSCalibur 
instrument.   
 
Tetramer staining 
Surface antibodies were purchased from Beckton Dickinson.  Tetramers 
were obtained from Beckman Coulter Immunomics.  106 CD8 T cells 
were resuspended in 100ul staining buffer (PBS containing 1% pooled 
human serum, 1% FBS and 5% goat serum) and Fc blocked for 10 
minutes using 1ug of anti-CD16/CD32 (FcγR11/III).  Cells were then 
incubated with 1:50 dilution of tetramer for 20 minutes at room 
temperature.  1ug of antibody to CD8 was added for an additional 10 
minutes.  Cells were washed and analyzed immediately using a BD 
FacsCaliber.  
 
In Vitro CTL Assay. 
Splenocytes from immunized animals were restimulated in 24 well plates 
(one spleen divided evenly among 24 wells) for 6 days with .5uM peptide 
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in R-10.  On day 6, cells were harvested and resuspended at 5 x 106/mL 
in R-10.  For target cell preparation, 106 EL4 cells in 100ul of R-10 were 
labeled with 10uM peptide plus 100uCi Cr51 for 1 hour at 37°C, shaking 
every 10 minutes.  EL4 cells were then washed 3 times in 1mL R-10 and 
resuspended at 105/mL.   5 x 103 EL4 cells were plated per well in a 
round bottom plate with serial dilutions of T cells, beginning with 5 x 105 
T cells per well (100 T cells to 1 target cell) and ending at 3.125 x 104 T 
cells per well (6.25 T cells to 1 target cell).  Plates were spun at 300rpm 
for 5 minutes and incubated at 37°C for 4.5 hours.  To harvest and 
measure radioactivity from the CTL assay, 100ul of supernatant from 
each well was pipetted into a sample plate for gamma measurement with 
100ul gamma scintillation fluid.  
  
RMA/S Assay. 
RMA/S cells were plated in T-75 flasks at 5 x 105/mL in D-10 at 37°C for 
9 hours and then placed at room temperature overnight with caps tightly 
sealed.  RMA/S cells were harvested and resuspended in R-10 at 5 x 
106/mL.   50ul of RMA/S cells were added to 50ul of peptide stock.  
Peptides stocks were made at 100uM, 10uM, 1uM, 100nM, 10nM.  
Duplicate tubes of RMA/S cells with peptide were incubated at room 
temperature for 45 minutes.  4mL of room temperature PBS was added 
to each tube and placed at either room temperature or 42°C for 5 hours.   
For FACS staining, cells were resuspended in 50ul staining buffer (PBS 
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containing 1% pooled human serum, 1% FBS and 5% goat serum) and 
Fc blocked for 10 minutes at room temperature using 1ug of anti-
CD16/CD32 (FcγR11/III).  1ul of biotin anti-mouse H-2Db antibody 
at.5mg/mL (BD Pharmingen, clone #28-14-8) was added and cells were 
incubated at room temperature for 15 minutes.  Cells were washed in 
4mL room temperature PBS and resuspended in 100ul staining buffer 
with 1ul streptavidin-PE at .5mg/mL (BD Pharmingen) and incubated for 
10 minutes at room temperature.   Cells were washed in 4mL room 
temperature PBS and analyzed by FACS.   
 
iTopia screen.    
Peptides were dissolved in 10mM DMSO and stored in aliquots at -20°C.  
Screening assays were carried out according to the manufacturer’s 
instructions using the provided reagents (Beckman Coulter).  In the 
initial binding assay, peptides were added individually at .1mM to plates 
coated with recombinant HLA molecules.  β2 microglobulin and FITC-
labeled anti-HLA class I were also added and the plates were then 
incubated for 18 hours at 21°C before being washed and read by a 
fluorescent plate reader (Ex 490nm, Em 520nm).  For affinity 
measurements, peptides were assayed as described above over eight 
serial dilutions.   For off-rate analysis, peptides were added to HLA 
coated plates as described above, incubated at 21°C for 18 hours and 
then washed and placed at 37°C for 0, .5, 1, 2, 4, 6, and 8 hours before 
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being read.  Data from each assay was analyzed in Prism using iTopia 
software and iScores were generated from a proprietary formula that 
takes into account measurements from all three assays.   
 
Peripheral blood isolation.   
Blood cells were collected by leukapheresis under a Rockefeller 
University IRB-approved protocol with informed consent.   PBMC were 
isolated by density gradient centrifugation over Ficoll-Hypaque 
(Pharmacia), and separated into T cell enriched (ER+) and T cell depleted 
(ER-) fractions by rosetting with neuraminidase-(Calbiochem, La Jolla, 
CA) treated sheep red blood cells (Colorado Serum Company, Denver, 
CO).  These cell fractions were cryopreserved by freezing in 10% human 
serum albumin/ 10%DMSO/RPMI. 
 
Human dendritic cell culture.   
Human dendritic cells (DC) were generated from peripheral blood 
mononuclear cells (PBMC).  Briefly, ER- cells were cultured in the 
presence of 100U/ml IL-4 (R&D Systems) and 100U/ml GM-CSF 
(Immunex) for 6 days to generate immature DC.  DC were harvested on 
day 6 and plated with PGE2 and TNFa to induce maturation.  After 2 




Human CD8 T cell isolation.   
Isolation of T cell fractions has been described (Albert, Jegathesan et al. 
2001).  Briefly, ER+ PBMC fractions were thawed incubated with anti-
CD8 MACS beads (Miltenyi Biotech, Auburn, CA) in 5%FBS/PBS, 
washed and run through a magnetic column to isolate antibody bound 
cells.  After washing the column, the positive cells were eluted by 
plunging the column. For experiments with adenovirus-immunized mice, 
spleens were harvested on day 13 and CD8 T cells were purified in a 
manner similar to the human protocol using anti CD8a beads (Miltenyi). 
 
In vitro stimulation of human peripheral blood T cells.   
CD8 T cells were incubated with autologous mDC at a 30:1 ratio in 24 
well plates with 10ug/ml peptide in AIM-V medium (Invitrogen) 
supplemented with 5%FBS.  After two days of culture recombinant 
human IL-2 (Chiron, CA) was added at 50IU/ml. 
 
Tetramer staining on human T cells.   
All HLA-A0201 tetramers were obtained from Beckman Coulter 
Immunomics.  1.0 x 106 patient PBMC were incubated with 1:20 dilution 
of tetramer for 20 minutes at room temperature.  Antibody to CD8 was 
then added to the cells for an additional 10minutes, washed and 
analyzed immediately using a BD FacsCaliber.  Cells were gated on the 
CD8+ population. 
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Quantitative western blot with human sera.   
For confirmation of Hu antibody titers in patients, quantitative western 
blot analysis with patient serum and recombinant HuD (rHuD) protein 
was performed as described previously (Dalmau, Furneaux et al. 1990).    
Briefly, 20ug of nickel-column purified his-tagged rHuD was loaded into 
a large, single well of a SDS-polyacrylamide gel and transferred to PVDF 
membrane.  The blocked membrane was incubated with dilutions of 
patient serum and horseradish peroxidase-conjugated secondary 
antibody and the signal visualized with a chemiluminescent substrate.  
The presence of reactivity to HuD, a 35kD protein, at a dilution greater 
than 1:1000 indicates a high titer Hu patient.  Sera from normal donors 
were used as a negative controls and known positive patient samples as 
positive controls. 
 
Tetramer+ T cell sorting. 
CD8 T cells were purified by positive selection (Miltenyi) from the frozen T 
cell fractions of patient leukapheresates.  1 x106 CD8 T cells were plated 
per well of a 24 well plate with 6000 peptide-pulsed, autologous mDC in 
AIM-V medium (Invitrogen) containing 5% FBS.  24 hours after initiation 
of the culture, IL-2 was added at 10U/ml.  After 8-12 days of culture the 
cells were harvested and incubated at 20 x 106/ml with a 1:20 dilution of 
tetramer.  The tetramer-positive population was sorted on a FACS Aria 
instrument (BD BioSciences).  After sorting, cells were placed into 
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culture in 96-well plates with autologous, peptide-pulsed PBMC and 
50U/ml IL-2.  After a recovery period of 8 days in culture, T cells were 






















CHAPTER III. IDENTIFICATION OF THE IMMUNODOMINANT H-2b 
CD8 T CELL EPITOPE OF HUD 
 
Introduction 
In order to study the mechanisms responsible for both T cell mediated 
neurologic degeneration and neuronal tolerance induction, we first 
sought to identify and characterize HuD-specific CD8 T cell clones.   A 
comprehensive screen of the entire HuD peptide library was performed in 
C57BL/6 mice, which lead to the identification of the immunodominant 
CD8 T cell epitope of HuD.  HuD-specific CD8 T cells were subjected to 
phenotypic and functional assays in order to characterize these cells and 
assess their ability to lyse HuD expressing targets in vitro and in vivo.   
 
Results 
Comprehensive screen to identify potential mouse H-2b HuD epitopes 
To determine if HuD-specific CD8 T cells are present in the mouse H-2b 
repertoire, we performed a comprehensive screen of the entire HuD 
peptide library in C57BL/6 mice.  C57BL/6 mice were chosen both for 
their ability to preferentially generate cell mediated rather than humoral 
immune responses and because most immunologically relevant 
transgenic strains are bred onto the C57BL/6 background.  The HuD 
peptide library consisted of 386 overlapping nonamers, including 
peptides derived from each known splice variant of the protein.  In order 
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to ensure that all HuD peptide-specific CD8 T cells present in the H-2b T 
cell repertoire were identified, we chose an aggressive immunization 
strategy that allowed for the expansion of peptide-specific CD8 T cells 
without the need for an APC or CD4 T cell help.  Mice were immunized 
with each individual HuD peptide emulsified in Titermax adjuvant.   After 
7 days, CD8 T cells were isolated from the draining lymph nodes and 
assessed for their ability to secrete IFNγ in an ELISPOT assay with 
cognate peptide-pulsed syngeneic stimulators. As a negative control, 
syngeneic stimulators were pulsed with an irrelevant peptide.   The 
secretion of IFNγ in response to cognate peptide indicated that there were 
HuD-specific CD8 T cells present in the T cell repertoire.  After screening 
the entire peptide library in this fashion, we identified 7 potential HuD 
CD8 T cell epitopes (Fig 1a).  
 
Identification of the immunodominant H-2b HuD epitope 
We next sought to identify naturally processed and presented HuD CD8 
T cell epitopes from these 7 potential peptides.   The presence of CD8 T 
cells specific for a given peptide in the H-2b repertoire does not by itself 
demonstrate natural processing and presentation.   In order to show 
natural processing and presentation, mice were immunized with a 
replication-deficient recombinant adenovirus expressing full length HuD 
to allow for in vivo processing and presentation of HuD epitopes onto 










Fig 1. p321 is the immunodominant CD8 T cell epitope of HuD.  (a) 
The entire HuD peptide library was screened in C57BL/6 mice.  7 
peptides (in bold) were identified as potential CD8 epitopes. (b) C57BL/6 
mice were immunized with AdVHuD plus PTx. 13 days after 
immunization, splenocytes were divided into 8 in vitro stimulation 
cultures and stimulated with each of the 7 HuD peptides or the 
immunodominant Bgal epitope p96. CD8 T cells were purified from 
stimulation cultures and plated (104 T cells/well) with cognate or 
irrelevant peptide-pulsed irradiated EL4 cells (5 x 104/well) in an IFNg 
ELISPOT assay. (c) As a control for in vitro priming, C57BL/6 mice were 
immunized with AdVBgal + PTx and stimulated in vitro with each of the 7 
















expand the population of peptide-specific CD8 T cells after adenovirus 
immunization, splenocytes from immunized animals were stimulated in 
vitro for 7 days with each of the 7 potential HuD epitopes.  CD8 T cells 
were then isolated from stimulation cultures and T cell activation was 
assessed in an IFNγ ELISPOT assay using cognate peptide-pulsed cells as 
stimulators (Fig 1b).    In order to ensure that a positive CD8 T cell 
response was the result of bona fide natural processing and presentation 
in vivo and not due to in vitro priming, we immunized a second group of 
mice with a replication-deficient recombinant adenovirus expressing the 
neo-antigen β-galactosidase (β-gal).  Splenocytes from β-gal immunized 
mice were stimulated in vitro with each of the 7 potential HuD epitopes 
and T cell activation was assessed in an IFNγ ELISPOT assay using 
cognate peptide-pulsed cells as stimulators (Fig 1c).  Of the 7 potential 
HuD epitopes, peptides 296 and 321 were able to prime CD8 T cells in 
vivo after adenovirus-HuD immunization.  Neither of these peptides 
elicited IFNγ secretion after immunization with adenovirus-β-gal, 
excluding the possibility of in vitro priming.  Based on the strength of the 
immune response to each of these two peptides, we concluded that 






Fig 2.   Pertussis toxin (PTx) is required for HuD-specific CD8 T cell 
priming.  C57BL/6 mice were immunized with AdVHuD alone (a) or 
AdVHuD plus PTx (b). 13 days after immunization, splenocytes were 
stimulated in vitro with p321. CD8 T cells were purified from stimulation 
cultures and plated (104 T cells/well) with cognate or irrelevant peptide-
pulsed dendritic cells (7 x 103/well) in an IFNg ELISPOT assay.  
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Pertussis Toxin is required for the generation of IFNγ-secreting HuD-specific 
CD8 T cells 
Immunization with adenovirus-HuD followed by in vitro stimulation with 
peptide proved to be an effective priming regiment for HuD-specific CD8 
T cells only if pertussis toxin was injected together with adenovirus.   
Immunizing with adenovirus-HuD alone did not generate IFNγ-secreting 
HuD-specific CD8 T cells even after p321 stimulation in vitro (Fig 2).    
Historically, pertussis toxin (PTx) has been used in the induction of EAE.   
EAE is arguably the most studied example of autoimmunity in the CNS, 
and thus it seemed logical to look to this model of disease for guidance in 
the generation of an immune response to HuD.   PTx was historically 
thought to act on EAE by serving to break down the blood brain barrier.   
We now understand that PTx increases adhesion molecule expression, 
thereby initiating leukocyte infiltration into the brain (Kerfoot, Long et al. 
2004).   Recent work has shown that PTx also induces maturation of 
dendritic cells, which promotes the differentiation of effector T cells (Hou, 
Wu et al. 2003).   In our attempt to generate cytotoxic CD8 T cells 
specific for HuD, this last effect was especially relevant.   In order to 
determine if PTx could assist in the production of HuD-specific effector T 
cells, mice were immunized with adenovirus-HuD alone or in 
combination with PTx.  Mirroring the EAE induction protocol, we injected 
PTx intraperitoneally (i.p.) on day 0 and day 2.   Splenocytes from 
immunized mice were then stimulated with p321 in vitro and assessed for 
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their ability to secrete IFNγ in an ELISPOT assay.   Mice that received 
adenovirus-HuD alone were unable to produce IFNγ-secreting CD8 T cells 
specific for HuDp321, whereas mice receiving PTx in combination with 
adenovirus-HuD generated a robust peptide-specific response (Fig 2).   
 
 
Db MHC I molecules present p321  
 
In order to further characterize HuDp321-specific CD8 T cells, we defined 
their MHC restriction.  This was an important issue to address with 
regard to designing tetramers for these cells.  A tetramer consists of a 
fluorochrome-tagged complex of four MHC I:peptide molecules and is 
able to bind specifically to the T cell receptor on a CD8 T cell.  Initially, 
we were able to predict the MHC I specificity of p321 by using publicly 
available prediction algorithms of peptide-MHC interactions. Based on its 
amino acid sequence, both the Bioinformatics and Molecular Analysis 
Section of the National Institutes of Health (BIMAS) and the University of 
Tubingen (SYFPEITHI) predicted p321 to bind Db MHC I.  To formally 
prove its MHC I restriction, we took advantage of a transgenic mouse 
strain that does not express Kb but retains expression of Db MHC I. 
H2bm1 mice are deficient in Kb expression due to a point mutation at the 
H-2 Kb locus.   Primary kidney cells derived from either wild type 
C57BL/6 mice or H2bm1 mice were pulsed with peptide in order to 
determine the MHC I restriction of p321.   As a positive control, we 
pulsed these same sets of stimulators (wild type versus H2bm1 kidney 
61 
cells) with the β-gal epitope p96, which binds to Kb MHC I molecules.  
Peptide-pulsed kidney cells were used as stimulators in an IFNγ ELISPOT 
assay with 3x-restimulated HuDp321-specific and β-galp96-specific CD8 
T cells (Fig 3).  As expected, β-galp96-specific CD8 T cells responded to 
wild type p96 pulsed stimulators but not to H2bm1 pulsed stimulators.  
HuDp321-specific CD8 T were able to respond equally well to wild type 
and H2bm1 p321 pulsed stimulators, confirming the prediction that p321 
is a Db restricted CD8 T cell epitope.  
 
Characterization of HuDp321-specific T cells 
Next, we assessed the affinity of HuDp321-specific CD8 T cells.   Using 
twice re-stimulated HuDp321-specific CD8 T cells, we measured the 
ability of these cells to recognize serial dilutions of peptide pulsed onto 
syngeneic dendritic cells in an IFNγ ELISPOT assay (Fig 4).  HuDp321-
specific CD8 T cells were able to secrete IFNγ in response to 10-9 M 
peptide, but below this concentration the response was lost.    Twice re-
stimulated β-galp96-specific CD8 T cells were also able to recognize 10-9 
M peptide (data not shown).  Thus, HuDp321-specific CD8 T cells are 
relatively high affinity T cells.  Finally, we asked if HuDp321-specific CD8 
T cells display a characteristic cell surface phenotype upon activation.  
We chose to look at CD25, CD69 and CD62L as markers of T cell 
activation. CD25 is the IL-2 receptor α chain and is up-regulated on 
activated T cells.   CD62L (or L-selectin) is a member of the selectin  
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Fig 3.   HuD p321 is presented on Db MHC I.  (a) Primary kidney cells 
from C57BL/6 mice (Db+/ Kb+) or transgenic Bm1 mice (Db+/ Kb- ) were 
irradiated and pulsed with p321 or p96 and used as stimulators in an 
IFNg ELIPOST assay (5 x 104/well) with 3x restimulated HuD p321-
specific or Bgal p96-specific  CD8 T cells (104/well).  
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Fig 4. HuDp321-specific CD8 T cells are high affinity T cells.  
HuDp321-specific CD8 T cells (2x restimulated) were plated in an IFNg 
ELISPOT assay (1.5 x 104/well) with C57BL/6 DC pulsed with serial 
dilutions of cognate peptide or NP as a negative control (104/well). 
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family of cell adhesion molecules and plays an important role in 
lymphocyte homing to peripheral lymph nodes.  It is a glycoprotein 
expressed on naïve T cells and down-regulated upon activation-induced 
differentiation. CD69 is an early activation antigen expressed by T cells. 
After stimulating HuDp321-specific CD8 T cells in vitro with cognate 
peptide for 7 days, we looked at expression of these three surface 
markers by flow cytometry (Fig 5).  As expected, both CD25 and CD69 
were up-regulated whereas CD62L was down-regulated on activated 
HuDp321-specific T cells.  In comparison, naïve T cells expressed no 
CD25 or CD69 but had high expression of CD62L, whereas activated β-
galp96-specific CD8 T cells displayed an identical cell surface phenotype 
to activated HuDp321-specific T cells (Fig 5).   Thus, HuDp321-specific 
CD8 T cells display a characteristic cell surface phenotype upon 
activation.   
 
Cytolytic function of HuDp321-specific T cells in vitro  
Having established that HuDp321-specific cells are relatively high affinity 
CD8 T cells with a characteristic activated cell surface phenotype, we 
next asked if they could function as effector CD8 T cells capable of lysing 
targets expressing cognate peptide.  The ability of CD8 T cells to lyse 
target cells in an antigen-dependent manner is a critical function of the 
immune system and an important part of the body’s defense against 
intracellular pathogens.  Activated CD8 T cells are aptly referred to as  
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Fig 5. Stimulated HuDp321-specific CD8 T cells display a 
characteristic cell surface phenotype.  In vitro stimulated HuDp321-
specific or Bgalp96-specific CD8 T cells were stained on day 7 for CD25, 
CD62L, and CD69.  Naïve T cells from the spleen of a C57BL/6 were 
used as a control. Plots are gated on CD8+ cells.    
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cytotoxic T lymphocytes (CTL).  We first examined the lytic ability of 
HuDp321-specific cells in vitro, using chromium labeled peptide-pulsed 
syngeneic cells as targets (Fig 6).  Splenocytes from adenovirus-HuD 
immunized animals were stimulated in vitro with p321.  Activated T cells 
were then cocultured with targets pulsed with cognate or irrelevant 
peptide.   For comparison, β-galp96-specific T cells were assessed for 
their lytic ability in an identical assay (Fig 6).  Both HuDp321-specific T 
cells and β-galp96-specific T cells were able to lyse target cells expressing 
cognate peptide.  β-galp96-specific T cells had a greater percent lysis 
compared to HuDp321-specific T cells, however this is explained by the 
larger number of p96-specific T cells present after in vitro stimulation.  
Stimulating splenocytes from adenovirus-HuD immunized animals in 
vitro with p321 results in approximately 1% p321-specific CD8 T cells 
(Fig 7).  In contrast, after in vitro stimulation of adenovirus-β-gal 
splenocytes with p96, 5-10% of the CD8 T cells are specific for p96 (Fig 
7).  For our in vitro CTL assay, bulk cells from in vitro stimulation 
cultures were counted and plated and thus there were roughly 10-fold 
more p96-specific CD8 T cells than p321-specific CD8 T cells per well.  
Given the results of the in vitro CTL assay, we can conclude that 
HuDp321-specific T cells are functional effectors capable of lysing target 




Fig 6.   HuDp321-specific CD8 T cells can kill in vitro.  C57BL/6 mice 
were immunized with AdVHuD plus PTx or AdVBgal plus PTx. 13 days 
after immunization, splenocytes were stimulated in vitro with cognate 
peptide (HuDp321 or Bgalp96).  On day 6, cells from stimulation cultures 
were plated with chromium labeled peptide-pulsed EL4 cells at the 
indicated E:T ratios.  EL4 cells were pulsed with 10uM Bgalp96 or 10uM 
HuDp321.  In red, three individual AdVHuD-immunized mice.  In blue, 
one representative AdVBgal-immunized mouse.   
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Fig 7.   Frequency of in vitro stimulated CD8 T cells.  C57BL/6 mice 
were immunized with AdVHuD plus PTx (a) or AdVBgal plus PTx (b). 13 
days after immunization, splenocytes were stimulated in vitro for 7 days 
with cognate peptide (HuDp321 or Bgalp96). CD8 T cells were purified 
from stimulation cultures and stained with Bgalp96 tetramer or 
HuDp321 tetramer.  Plots are gated on CD8 T cells.  
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Cytolytic function of HuDp321-specific T cells in vivo 
If HuD-specific CD8 T cells are responsible for generating neuronal 
autoimmunity in anti-Hu syndrome, these cells must be capable of 
functioning as cytotoxic T cells in vivo.   In order to examine the lytic 
ability of HuD-specific cells in vivo, we adoptively transferred T cells into 
a syngeneic host and measured their ability to lyse a population of 
peptide-pulsed target cells.  Targets consisted of C57BL/6 splenocytes 
labeled with carboxyfluoroscein succinimidyl ester (CFSE) and pulsed 
with peptide.  Two populations of target cells were injected into the host, 
a cognate peptide-pulsed population and an irrelevant peptide-pulsed 
control population.  These two populations were distinguished by their 
CFSE intensity (p321-pulsed targets were labeled with a high 
concentration of CFSE [CFSEhi] and p96-pulsed targets were labeled with 
a low concentration of CFSE [CFSElo]) and were mixed at a 1:1 ratio 
before being injected intravenously.  6 to 18 hours after target injection, 
the host animal was sacrificed and the amount of each target population 
remaining in vivo was measured by flow cytometry (Fig 8).   In a host that 
received HuDp321-specific CD8 T cells, the p321-pulsed CFSEhi 
population was reduced, demonstrating in vivo antigen-dependent lysis 
by HuDp321 T cells.   Similarly, in a host containing β-galp96-specific T 
cells, the p96-pulsed CFSElo population was eliminated.   Mirroring the 
results of our in vitro CTL assay, β-galp96-specific T cells had a greater 
amount of specific lysis compared to HuDp321-specific cells, again due 
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to the increased numbers of p96-specific cells after in vitro stimulation.   
In order to enhance the effector function of our transferred T cells, we 
injected mature C57BL/6 dendritic cells (DC) pulsed with p321 along 
with stimulated HuDp321-specific CD8 T cells.  We reasoned that this 
peptide-pulsed DC population would provide an in vivo re-stimulation for 
HuDp321-specific T cells, thereby increasing their numbers and 
enhancing the amount of lysis.    Host animals were injected with in vitro 
stimulated HuDp321-specific cells in combination with DCs pulsed with 
p321 or, as a control, DCs pulsed with p96.  Similarly, a second group of 
animals was injected with stimulated β-galp96-specific T cells together 
with peptide-pulsed DCs.  The addition of cognate peptide-pulsed DCs 
increased the amount of lysis by both HuDp321-specific T cells and β-
galp96-specific T cells (Fig 8).  This increase was not due to non-specific 
stimulation of T cells by DCs, as the addition of irrelevant peptide-pulsed 
DCs did not increase the lytic ability of our T cells.  We chose to assess 
target lysis by T cells in vivo in two different strains of mice: wild type 
C57BL/6 mice and transgenic Rag-/- animals that are deficient for the 
Rag-1 gene and therefore lack mature T cells and B cells.  Rag-/- mice 
were used because we were concerned that the endogenous T cell 
repertoire, which includes regulatory T cells, could potentially serve to 
inhibit our transferred cells and suppress their effector function.   Our 
initial in vivo CTL experiment used the Rag-/- strain in order to provide 
an empty host devoid of endogenous T cells (Fig 8).   Transferred  
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Fig 8.  DC pulsed with cognate peptide enhance killing by HuDp321-
specific CD8 T cells in vivo.  5 x 106 HuDp321-specific or Bgalp96-
specific in vitro stimulated CD8 T cells were adoptively transferred into 
Rag-/- mice with 2 x 106 C57BL/6 bone marrow derived DC pulsed with 
cognate or irrelevant peptide. Mice also received PTx and IL-2.  Nine days 
post transfer, mice were injected with CFSE-labeled syngeneic 
splenocytes pulsed with p321 or p96.  p321-pulsed targets were labeled 
with a high fluorescence intensity and p96-pulsed targets were labeled 
with a low fluorescence intensity.  7 hours after target injection, 
splenocytes were analyzed by FACS for in vivo target cell lysis  
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HuDp321-specific CD8 T cells were efficient at lysing targets in a Rag-/- 
host.  In order to examine the issue of suppression by the endogenous 
C57BL/6 T cell repertoire, we performed a second experiment, comparing 
the lytic ability of HuDp321-specific T cells in a Rag-/- versus a wild type 
host (Fig 9).   Our transferred cells were equally potent cytotoxic effectors 
in either strain of mice.   We concluded that once activated, HuDp321-




We have shown that there are HuD-specific CD8 T cells present in the H-
2b repertoire, and that peptide 321 represents the immunodominant 
epitope of the HuD protein.   Peptide 321 is a Db restricted epitope, and 
HuDp321-specific CD8 T cells are high affinity cells that display a 
characteristic cell surface phenotype upon in vitro stimulation.  
Immunization with recombinant adenovirus-HuD followed by in vitro 
peptide stimulation allowed for the activation of HuDp321-specific CD8 T 
cells.   Pertussis toxin was also required for successful priming in vivo, 
since immunization with adenovirus-HuD alone did not result in 
HuDp321-specific T cell activation, even after in vitro stimulation.  In vitro 
stimulated HuD-specific CD8 T cells were shown to be functional 
cytotoxic T cells capable of secreting IFNγ and lysing target cells in an 
antigen-dependent manner.   There was no loss of lytic ability in vivo  
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Fig 9. HuD p321-specific CD8 T cells can kill in vivo.  (a) 5 x 106 HuD 
p321-specific in vitro stimulated CD8 T cells were adoptively transferred 
into Rag-/- mice with 2 x 106 C57BL/6 bone marrow derived DC pulsed 
with p321. Mice also received PTx and IL-2.  Eight days post transfer, 
mice were injected with CFSE-labeled syngeneic splenocytes pulsed with 
p321 or p96.  p321-pulsed targets were labeled with a high fluorescence 
intensity and p96-pulsed targets were labeled with a low fluorescence 
intensity.  6 hours after target injection, splenocytes were analyzed by 
FACS for in vivo target cell lysis. (b) as in (a) except that WT C57BL/6 
mice were used as recipients of adoptively transferred HuDp321-specific 
CD8 T cells.  
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when stimulated HuD-specific CD8 T cells were transferred into a wild 
type host, suggesting that once expanded and activated, these cells are 
































CHAPTER IV.  TOLERANCE TO HUD IN THE MOUSE 
  
Introduction  
The immune system is designed to distinguish self proteins from foreign 
antigens.  Effective immune responses to self tissues are necessarily 
avoided in order to guard against the development of deleterious 
autoimmune disease.   The central nervous system is not ignored by the 
immune system, as activated T cells are allowed access to the CNS in 
order to defend against infection.   Immunosurveillance of the CNS poses 
the risk of developing autoimmune neurodegeneration mediated by 
neuron-specific T cells. Tolerance induction to neuronal antigens is 
poorly understood.  Patients with anti-Hu syndrome have aggressive 
neuronal autoimmunity, presumably mediated by HuD-specific T cells.   
The fact that a majority of SCLC patients fail to mount an immune 
response to HuD despite the presence of this protein in all tumors 
suggests that tolerance induction to HuD is normally maintained.  In 
patients with the Hu syndrome, tolerance would necessarily be broken to 
allow autoreactive lymphocytes to target HuD expressing neurons.   
Having identified and characterized HuD-specific CD8 T cells in mice, we 
sought to investigate tolerance induction to HuD.  Our initial 
experiments showed that in vitro stimulation with peptide subsequent to 
immunization with full-length protein and pertussis toxin was required 
to detect activated HuD-specific CD8 T cells.   The need for in vitro 
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stimulation and PTx suggested that HuD-specific CD8 T cells are subject 
to tolerance induction.  In order to formally show tolerance to HuD, we 
took advantage of HuD-deficient transgenic mice.    In addition, we 
sought to compare tolerance induction to HuD versus HuA.   HuA is a 
closely related Hu family member with high sequence homology to HuD, 
however the protein is not neuron-specific but ubiquitously expressed.  
Given the difference in expression between HuD and HuA, we reasoned 
that the two proteins might undergo different forms of tolerance 
induction.  We hypothesized that tolerance to HuA should be stricter 
compared to HuD since the protein is present in all tissues and not 
restricted in expression to neurons.   
 
Results 
HuDp321 specific T cells do not secrete IFNγ ex vivo after adenovirus-HuD 
immunization  
IFNγ secretion is a hallmark of T cell activation.  We have already shown 
that HuDp321-specific CD8 T cells are capable of secreting IFNγ upon 
immunization with recombinant adenovirus, however these results relied 
on pertussis toxin treatment and in vitro stimulation with peptide.  
Immunization followed by stimulation ex vivo, outside of the host’s 
normal immune system, serves to release cells from any inhibition felt in 
vivo.   We have shown activation of HuD-specific CD8 T cells subsequent 
to removing these cells from their in vivo environment (in vitro stimulated 
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HuDp321-specific CD8 T cells secrete substantial amounts of IFNγ in 
response to cognate peptide and are able to lyse target cells in an 
antigen-dependent manner), however we have yet to assess the activation 
of these cells directly after immunization with adenovirus-HuD.  An 
inability to activate HuD-specific CD8 T cells in vivo would imply immune 
tolerance to the HuD protein.  In order to determine if HuDp321-specific 
T cells can be activated in vivo, we immunized mice with adenovirus-HuD 
together with pertussis toxin and isolated CD8 T cells from the spleen.  
CD8 T cells were plated directly in an IFNγ ELISPOT assay with cognate 
peptide-pulsed stimulators (Fig 1).  As a control, mice were immunized 
with adenovirus-β-gal.   β-gal is a neo-antigen and therefore not subject 
to tolerance induction in vivo.   After immunization with adenovirus-β-gal 
without in vitro p96 stimulation, we were able to show robust IFNγ 
secretion by β-galp96-specific CD8 T cells.   In contrast, we saw no IFNγ 
secretion by HuDp321-specific CD8 T cells after immunization with 
adenovirus-HuD (Fig 1).  The inability to activate HuD-specific T cell in 
vivo after immunization suggests that mice are tolerized to the HuD 
protein. 
 
HuDp321 specific T cells expand in vivo after immunization with HuD 
Because we can isolate T cells from mice immunized with adenovirus-
HuD and generate IFNγ-secreting CD8 T cells after p321 stimulation in 
vitro, we can be certain that a population of HuD-specific CD8 T cells  
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Fig 1.   HuD p321-specific CD8 T cells do not secrete IFNg directly 
ex vivo after adenovirus-HuD immunization.   C57BL/6 mice were 
immunized with AdVHuD or AdVBgal (i.d.) + PTx .  13 days later, CD8 T 
cells were isolated from the spleen and plated in an IFNg ELISPOT assay 
(2 x 105/well) with mDC pulsed with 10uM peptide (7 x 103/well).   
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exists in the H-2b repertoire.  The fact that we cannot see IFNγ secretion 
directly ex vivo after immunization implies that there are tolerance 
mechanisms acting to suppress HuD-specific T cell activation.   Both 
central and peripheral tolerance mechanisms protect the body from auto-
reactive immune responses.   Central tolerance serves to delete any self-
reactive T cell clones from the repertoire during development in the 
thymus, whereas peripheral tolerance actively suppresses those self-
reactive T cells that escape thymic deletion to circulate in the periphery.    
Because we were unable to detect HuDp321-specific T cells by IFNγ 
secretion directly after immunization, we instead used tetramer to 
visualize and quantify these cells in mice after adenovirus-HuD 
immunization.   For comparison, a second group of mice was immunized 
with influenza virus (e.g. flu).  We measured the number of HuDp321-
specific CD8 T cells or NP-specific CD8 T cells by tetramer directly ex vivo 
and after in vitro stimulation (Fig 2).    NP is a Db restricted CD8 T cell 
epitope of influenza.  Splenocytes for adenovirus-HuD or flu immunized 
animals were stained directly ex vivo with both HuDp321 tetramer and 
NP tetramer.   We observed the expected frequency of NP-specific T cells 
(1.5% of the total CD8 T cell repertoire), and we could expand this 
population by in vitro stimulation with NP.  In comparison, after 
adenovirus-HuD immunization we observed .04% HuDp321-specific CD8 
T cells.  This population could be expanded in vitro by p321 stimulation.  
Expansion of HuDp321-specific T cells depended on the presence of HuD  
80 
Fig 2.  HuDp321-specific CD8 T cells expand in vivo after 
immunization with adenovirus-HuD.  C57BL/6 mice were immunized 
with either AdVHuD + PTx or influenza virus (naïve mice were left 
untreated).  15 days after immunization, CD8 T cells were isolated from 
the spleen and stained directly ex vivo with anti-CD8 antibody and 
tetramer.  Each population of CD8 T cells was stained with NP-Db 
tetramer and p321-Db tetramer separately.  Splenocytes from each 
mouse were also stimulated in vitro with cognate peptide for 7 days.  
Naïve mice were stimulated with p321.  CD8 T cells from in vitro 
stimulation cultures were stained with anti-CD8 antibody and tetramer.  
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in vivo, as in vitro stimulation of naïve splenocytes with p321 did not 
generate a population of HuDp321-specific cells (Fig 2).     Thus, there is 
visible, albeit slight, response in vivo of HuDp321-specific CD8 T cells 
after immunization, but this population is readily expanded upon in vitro 
stimulation with antigen.  
 
HuAp268-specific T cells are absent from the H-2b repertoire  
To better understand the mechanisms behind tolerance to the Hu 
proteins, we compared the immune response to HuDp321 versus its 
homologous epitope in HuA, p268.  HuAp268 differs from HuDp321 at a 
single amino acid position (Fig 3a). The anchor residues that stabilize the 
peptide-MHC interaction are conserved between the two peptides so that 
both should bind MHC I with similar affinity.  In order to ensure that 
HuAp268 binds efficiently to MHC I molecules, we assessed the affinities 
of p268 versus p321 using RMA/S cells incubated with serial dilutions of 
peptide (Fig 3b).  HuAp268 had a higher affinity for Db MHC I compared 
to HuDp321, which bound Db with similar affinity compared to the 
positive control peptide NP.   Unlike HuD, HuA is not confined to 
neurons but is ubiquitously expressed.  We hypothesized that immune 
tolerance to this protein would be stricter compared to a neuron-specific 
protein like HuD.   To determine if HuAp268-specific CD8 T cells are 
present in the H-2b repertoire or deleted as a result of central tolerance 
induction, we immunized C57BL/6 mice with Titermax-peptide and  
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Fig 3.   HuA p268 binds with high affinity to Db MHC I. (a) HuDp321 
and homologous peptides in HuA, HuB, HuC.  (b) RMA/S cells were 
incubated with serial dilutions of peptide and stained for Db MHC I. HuD 
p321 and its homologous epitope in HuA (p268) were assayed. The A2.1 
epitope of influenza (M1) was used as a negative control. The Db epitope 
of influenza (NP) was used as a positive control.   
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looked for IFNγ secretion by CD8 T cells in an ELISPOT assay (Fig 4a).   
Whereas HuDp321-specific and NP-specific T cells were clearly present in 
the repertoire, HuAp268 cells were absent.    The absence of HuAp268-
specific T cells suggests that these cells were centrally deleted.   Given 
the high affinity of p268 for MHC I, and its sequence homology to p321, 
we can assume that this peptide is naturally processed and presented.   
The complete absence of HuAp268 cells from the T cell repertoire is 
indicative of central tolerance to HuA.   
 
HuDp321 specific T cells do not cross-react with HuA 
Patients with the Hu syndrome succumb to autoimmunity directed 
against the nervous system but not against peripheral tissues, implying 
that the immune response to HuD does not cross-react with HuA.  To 
investigate cross-reactivity to HuA, we asked if HuDp321-specific CD8 T 
cells are able to respond to primary kidney cells infected with 
adenovirus-HuA (Fig 4b).  HuDp321-specific CD8 T cells were 
restimulated three times in vitro and plated in an IFNγ ELISPOT assay 
with kidney cells infected with either adenovirus-HuA, adenovirus-HuD, 
or a control adenovirus expressing GFP.  Only kidney cells infected with 
adenovirus-HuD were able to elicit IFNγ secretion from HuDp321-specific 
CD8 T cells. The lack of cross-reactivity to HuA is in accordance with 
clinical data and supports our model of autoimmunity directed 
exclusively against neurons. 
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Fig 4.   HuA p268-specific CD8 T cells are absent from the H-2b 
repertoire.  (a) C57BL/6 mice were immunized with individual peptides 
(NP, HuA p268, or HuD p321) in titermax adjuvant. 7 days later, 
draining lymph node CD8 T cells were plated in an IFNg ELISPOT assay 
(2 x 105/well) with peptide-pulsed EL4 cells (5 x 104/well).  (b) HuD 
p321-specific CD8 T cells (3x restimulated) were plated in an IFNg 
ELISPOT assay (104/well) with primary kidney cells infected with 
recombinant adenovirus (5 x 104/well).   
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Mice are tolerized to HuD 
We have shown that HuD-specific CD8 T cells exist in the H-2b 
repertoire, although there appears to be tolerance to the protein since in 
vitro stimulation is required for their activation.   To definitely prove 
tolerance to HuD, we took advantage of the transgenic HuD-deficient 
mouse (Akamatsu, Fujihara et al. 2005).  HuD-/- mice were generated by 
targeted disruption of the HuD gene.  Phenotypically, HuD-/- pups are 
indistinguishable from their wild type littermates.  By 4-8 weeks of age, a 
70-80% of HuD-/- mice exhibit an abnormal clasping of the hind limbs 
when suspended by the tail, suggesting cortical and/or basal ganglia 
defects.  Immunologically, the absence of HuD in vivo would prevent any 
form of tolerance to the protein.  If HuDp321-specific CD8 T cells 
experience tolerance induction, then elimination of the HuD protein 
should result in efficient expansion and activation of these cells in vivo.  
To assess tolerance to HuD, we immunized HuD-/- versus wild-type mice 
with adenovirus-HuD and measured IFNγ secretion by HuDp321-specific 
CD8 T cells directly ex vivo (Fig 5a).   HuDp321-specific CD8 T cells from 
HuD-deficient mice exhibited a strong response ex vivo, whereas HuD+/+ 
mice were unable to generate activated HuDp321-specific cells directly 
after immunization (Fig 5a).   To ensure that the lack of an ex vivo 
response in wild type mice was not due to an ineffective immunization, 
portions of the spleens from individual mice were stimulate in vitro with 
p321 (Fig 5b).  Wild type mice were able to  
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Fig 5.   C57BL/6 mice are tolerized to HuD.  (a) HuD-/- , HuD+/+ and 
WT C56BL/6 mice were immunized with AdVHuD + PTx.  13 days after 
immunization, CD8 T cells were isolated from the spleens and plated in 
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x 
105/well).  (b) half of the spleens from mice immunized in (a) were 
stimulated in vitro with p321.  After 7 days, CD8 T cells were isolate from 
stimulation cultures and plated in an IFNg ELISPOT assay (104/well) 
with peptide pulsed EL4 cells (5 x 104/well).   
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generate activated HuDp321-specific CD8 T cells after in vitro 
stimulation.  Taken together, these results show that HuD-specific CD8 T 
cells are subject to tolerance induction in vivo.       
 
HuC-deficient mice remain tolerized to HuD 
Tolerance can be achieved by the generation of CD4 regulatory T cells.   If 
regulatory T cells are responsible for tolerance induction to HuD, these 
cells may be specific for CD4 T cell epitopes shared between HuD and 
other family members.  In order to determine if tolerance to HuD was 
dependent on the presence of HuD protein specifically or induced by 
other Hu family members, we took advantage of the HuC knockout 
mouse.  The HuD and HuC proteins are closely related, however the HuC 
homolog of HuDp321 differs by a single amino acid (Fig 3a).  In fact, the 
amino acid sequence of p321 is not found in any other Hu family 
member.   If tolerance depends on other T cell epitopes aside from 
HuDp321, then deletion of the HuC gene could result in a loss of 
tolerance to HuD.  In order to investigate tolerance induction by other Hu 
family members, we immunized mice deficient for HuC with adenovirus-
HuD and asked if HuDp321-specific CD8 T cells were activated in vivo 
(Fig 6).  HuC-deficient animals showed no response to HuDp321 directly 
ex vivo (Fig 6a).  After stimulating splenocytes in vitro with p321, 
however, HuDp321-specific CD8 T cells were able to secrete IFNγ, 
ensuring an effective immunization (Fig 6b).   We can conclude that  
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Fig 6.   HuC-/- mice remain tolerized to HuD. (a) HuC-/- and HuC+/- 
mice were immunized with AdVHuD + PTx.  13 days after immunization, 
CD8 T cells were isolated from the spleens and plated in an IFNg 
ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x 
104/well).  (b) splenocytes from mice immunized in (a) were stimulated in 
vitro with p321.  After 7 days, CD8 T cells were isolate from stimulation 
cultures and plated in an IFNg ELISPOT assay (104/well) with peptide 
pulsed EL4 cells (5 x 104/well).   
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tolerization of HuDp321-specific CD8 T cells does not require HuC, but is 
dependent on HuD specifically.   
 
CD4 depletion does not overcome tolerance to HuD 
Peripheral tolerance induction can depend on active suppression of 
autoreactive clones by regulatory T cells.    In order to investigate the role 
of regulatory T cells in maintaining tolerance to HuD, we depleted the 
CD4 T cell population in vivo prior to adenovirus-HuD immunization (Fig 
7).   CD4 depletion was achieved by injecting mice with anti-CD4 
antibody, followed by immunization with adenovirus-HuD or adenovirus-
β-gal. We measured activation of HuDp321-specific CD8 T cells in an 
IFNγ ELISPOT assay.   To assess the efficacy of our depletion regiment, 
splenocytes were analyzed for the presence of CD4 and CD8 T cells.   
There were no CD4 T cells remaining in the depleted mice two weeks 
after immunization with adenovirus-HuD (Fig 7). The absence of CD4 T 
cells did not overcome tolerance to HuD, as we saw no IFNγ secretion 
directly ex vivo in response to p321. It is important to note that CD4 
depletion does not specifically target regulatory T cells but instead 
eliminates the entire CD4 T cell population.  The absence of CD4 T cells 
did not effect T cell priming by immunization with recombinant 
adenovirus, since CD4-depleted mice immunized with adenovirus-β-gal 
were able to generate activated β-gal-specific CD8 T cells (Fig 7).   Still, β- 
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Fig. 7.  CD4 depletion does not overcome tolerance to HuD.  
C57BL/6 mice were injected with anti-CD4 antibody GK1.5 
(500ug/mouse) i.p. on days -7 and -4.  On day 0, mice were immunized 
with AdVHuD or AdVBgal + PTx (2 mice per group).  13 days after 
immunization, CD8 T cells were isolated from the spleens and plated in 
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed DC (7 x 
103/well).  Splenocytes from each mouse were analyzed on day 13 by 
FACs to ensure CD4 depletion.  Splenocytes from control mice 
immunized with AdVHuD or AdVBgal + PTx were analyzed by FACs (No 
depletion).  
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gal is not an autoantigen like HuD, so that CD8 T cell priming to HuD 
may require CD4 T cells whereas CD8 T cell priming to β-gal does not.   
 
AIRE does not regulate tolerance to HuD 
In order to explore the role of AIRE in mediating tolerance to HuD, we 
immunized AIRE-deficient mice with adenovirus-HuD and assessed 
HuDp321-specific CD8 T cell activation directly ex vivo.  We reasoned 
that if AIRE were to regulate tolerance to HuD, then AIRE-deficient 
animals should mount an immune response similar to that of HuD-
deficient mice.    After immunization of an AIRE-deficient mouse and its 
wild-type littermate with adenovirus-HuD, we saw no response directly 
ex vivo to HuDp321 in either animal (Fig8a).  A portion of the spleen from 
each animal was stimulated in vitro with p321 in order to ensure that our 
immunization was successful and that AIRE mice did not have gross 
immunologic abnormalities that prevented HuD CD8 T cell priming.  
After in vitro stimulation, both the AIRE-deficient mouse and its wild type 
littermate generated a typical HuDp321-specific CD8 T cell response (Fig 
8b).    We can conclude that AIRE does not influence tolerance induction 
to HuD.   
 
Summary 
HuDp321-specific CD8 T cells were not detectable by IFNγ secretion 
directly ex vivo after immunization with adenovirus-HuD but could be  
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Fig 8.   AIRE does not regulate tolerance to HuD.  (a) AIRE-/- and 
AIRE+/+ mice were immunized with AdVHuD + PTx.  13 days after 
immunization, CD8 T cells were isolated from the spleens and plated in 
an IFNg ELISPOT assay (2 x 105/well) with peptide-pulsed EL4 cells (5 x 
104/well).  (b) splenocytes from mice immunized in (a) were stimulated in 
vitro with p321.  After 7 days, CD8 T cells were isolate from stimulation 
cultures and plated in an IFNg ELISPOT assay (104/well) with peptide 
pulsed EL4 cells (5 x 104/well).   
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expanded and activated in vitro upon stimulation with peptide.  Tolerance 
to HuD is normally maintained, since immunization of HuD-deficient 
mice with adenovirus-HuD generated a robust ex vivo response from 
HuDp321-specific CD8 T cells that did not require in vitro stimulation.   
Aggressive immunization of wild type mice with peptide 321 emulsified in 
Titermax adjuvant elicited a strong ex vivo IFNγ response from HuDp321-
specific CD8 T cells, demonstrating that these cells exist in the repertoire 
and are not subject to central tolerance induction.  In comparison, 
HuAp268-specific CD8 T cells were not detectable after immunization 
with Titermax-peptide, which is indicative of thymic deletion.   HuAp268 
binds with higher affinity to Db MHC I compared to HuDp321, and amino 
acid residues flanking the two peptides are conserved, suggesting that 
both are naturally processed and presented in a similar manner.   There 
is a single amino acid difference between the two peptides at the fourth 
residue, which is thought to affect the interaction with the T cell 
receptor.    Central deletion of HuAp268 reactive T cells is critical to 
prevent peripheral autoimmune disease, given the ubiquitous expression 
pattern of the protein.    CD8 T cells specific for a neuronal antigen like 
HuD escape central tolerance induction and are instead subjected to 
regulation in the periphery.   The fact that patients with the Hu 
syndrome never succumb to peripheral autoimmunity suggests that the 
HuD-specific immune response is unable to cross-react with HuA.  We 
have formally shown that HuDp321-specific CD8 T cells do not recognize 
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processed and presented HuA.    Thus, the immune response to HuD is 
neuron-specific, and tolerance to this neuronal antigen is critical to 





































CHAPTER V. HUD-SPECIFIC CD8 T CELLS IN THE CNS 
 
Introduction 
Patients with the Hu syndrome develop neurologic symptoms that affect 
discrete areas of the nervous system including the dorsal root ganglia, 
limbic system, cerebellum, brainstem, motor or autonomic nervous 
system.   Most patients go on to develop multifocal neuronal 
degeneration and die from neuronal causes, on average, seven months 
after diagnosis.  The disease is characterized by neuronal loss and 
inflammatory infiltrates of the nervous system.   The presence of high 
titer antibodies to Hu serves as a diagnostic tool, however the role of 
antibodies in disease pathogenesis remains unclear.   Given the 
intracellular nature of HuD, it seems likely that CD8 T cells play an 
important role in disease pathogenesis.  We have identified the 
immunodominant CD8 T cell epitope of HuD in order to model CD8 T cell 
mediated neuronal degeneration in mice.   Upon adoptive transfer of 
HuD-specific CD8 T cells into recipient mice, we sought to assess the 
ability of these cells to traffic to the CNS.  In addition, we measured 
recruitment of peripheral APCs and upregulation of MHC I and MHC II 
molecules on resident microglia, as these are hallmarks of inflammatory 
CNS diseases.    In order to assess neuronal loss, we sent tissue sections 




Adoptive transfer of HuD-specific CD8 T cells 
In order to study the ability of HuD-specific CD8 T cells to traffic to the 
central nervous system and target HuD expressing neurons, we 
developed a system that relied on the adoptive transfer of labeled CD8 T 
cells into a host animal (Fig 1a).   Based on the results of our in vivo CTL 
experiments, we opted to transfer stimulated CD8 T cells along with 
syngeneic dendritic cells pulsed with cognate peptide.   Host animals also 
received pertussis toxin and exogenous IL-2.   IL-2 was used for its 
ability to augment the function of transferred T cells.   In a published 
model of tumor regression mediated by adoptive transfer of self-reactive 
CD8 T cells, it was shown that IL-2 increases the number and function of 
self-specific T cells (Overwijk, Theoret et al. 2003).   Given these results, 
we reasoned that IL-2 could support the expansion and cytolytic ability 
of transferred HuD-specific CD8 T cells.  In order to distinguish 
transferred CD8 T cells from the host repertoire, we transferred 
stimulated CD8 T cells derived from the congenic Thy1.1 mouse strain.  
Thy1.1 is an isoform of the Thy1 glycoprotein found exclusively on T 
cells; wild-type C56BL/6 mice carry the Thy1.2 isoform, which is easily 





HuDp321-specific CD8 T cells can traffic to the central nervous system  
In our initial adoptive transfer experiment we used Rag-/- mice as the 
recipients of CD8 T cells.   Rag-/- mice received β-galp96-specific or 
HuDp321-specific CD8 T cells together with cognate peptide-pulsed DCs, 
pertussis toxin and IL-2.   To assess the purity of transferred CD8 T 
cells, we stained a representative sample of cells for Thy1.1 and CD8 T 
cell markers (Fig 1b).  Roughly 90% of the transferred cells were positive 
for Thy1.1 and CD8.  To assess CD8 T cell trafficking to the nervous 
system, we sacrificed recipients one month after transfer and isolated 
cells from brain (Fig 2).   For comparison, we measured CD8 T cell 
trafficking to the spleen.  Both Thy1.1 β-gal-specific CD8 T cells and 
Thy1.1 HuD-specific CD8 T cells were found in the spleens of recipients 
one month post-transfer, ensuring that our adoptive transfer strategy 
allowed for the survival and persistence of transferred T cells.  Thy1.1 T 
cells in the spleens expressed high levels of the CD8 co-receptor, as 
expected.  When we examined the brains of recipient animals, we 
detected Thy1.1 transferred T cells, indicating that these cells could 
indeed traffic to the central nervous system.  Trafficking to the brain was 
not dependent on the presence of antigen behind the blood brain barrier, 
as both β-gal-specific CD8 T cells and HuD-specific CD8 T cells were 
found in the CNS.   Thy1.1 cells in the brain had down-regulated the 
CD8 co-receptor (Fig 2).  Down-regulation of CD8 was not antigen-
dependent but perhaps a result of the brain’s cytokine milieu.  The CD8  
98 
Fig 1. Adoptive transfer of HuDp321-specific CD8 T cells. (a) for 
adoptive transfer experiments, C57BL/6 mice (WT or Rag-/-) received 5 x 
106 in vitro stimulated Thy1.1 HuDp321-specific or Bgalp96-specific CD8 
T cells (i.v.) with 2 x 106 cognate peptide-pulsed DC (i.v), PTx, and IL-2.  
(b) to assess the purity of transferred CD8 T cells, transferred cells were 
stained for Thy1.1 and CD8 T cell markers.  
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Fig 2.  Transferred CD8 T cells traffic to the CNS.  Rag-/- mice 
received an adoptive transfer of HuD-specific (red mouse) or Bgal-specific 
(blue mouse) Thy1.1 CD8 T cells as described in Fig 1a.  One month 
later, cells from the spleens and brains of perfused recipients were 
stained for Thy1.1 and CD8 T cells markers. 
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co-receptor is an important component of the T cell receptor signaling 
pathway that affects proliferation and activation of CD8 T cells.   Down-
regulation of the CD8 molecule in the CNS may be a means of 
suppressing T cells and thereby inhibiting potentially damaging immune 
responses.   
 
HuDp321-specific CD8 T cells from the central nervous are capable of 
secreting IFNγ in vitro 
Given that transferred CD8 T cells in the brain down-regulate the CD8 
co-receptor, we asked if these cells were permanently suppressed as a 
result of trafficking to the CNS.   IFNγ secretion was used as an 
indication of T cell activation. CD8 T cells isolated from the brain were 
assessed for the ability to secrete IFNγ in response to cognate peptide in 
an ELISPOT assay (Fig 3).  As a positive control, we isolated cells from 
the spleens of recipients and measured IFNγ secretion.  Both β-gal-
specific CD8 T cells and HuD-specific CD8 T cells isolated from the 
spleen were capable of producing IFNγ in response to cognate peptide.  
Cells from the brain were also able to secrete IFNγ, demonstrating that 






Fig 3.  Transferred CD8 T cells in the CNS are not anergic.  WT 
C57BL/6 mice received an adoptive transfer of Thy1.1 HuD-specific (red 
mouse) or Bgal-specific (blue mouse) CD8 T cells as described in Fig 1a.  
One month later, bulk cells from the spleens and brains of perfused 
recipients were plated in an IFNg ELISPOT assay with 1ug cognate or 
irrelevant peptide.   Cells were also stained for Thy1.1.  
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HuDp321-specific CD8 T cells in the central nervous system are not 
sufficient for the induction of inflammation and neurologic degeneration   
From our previous results we can conclude that CD8 T cells specific for 
HuD are able to traffic to the CNS after adoptive transfer but are unable 
to cause gross neurologic degeneration despite the presence of cognate 
antigen in the brain.   Clearly, there is an additional requirement apart 
from HuD-specific CD8 T cell entry into the brain that is required for 
autoimmune destruction of HuD expressing neurons.   In EAE, which is 
characterized by CD4 T cell mediated autoimmune destruction of myelin 
in the CNS, T cell infiltration is accompanied by inflammation behind the 
blood brain barrier.  Hallmarks of this inflammatory response are 
recruitment of peripheral APCs to the brain and up-regulation of MHC I 
and MHC II molecules on resident microglia.   Because there were no 
apparent signs of neuronal loss in our adoptive transfer recipients, we 
asked if this was do to a lack of inflammation in the CNS.  As a measure 
of inflammation in the CNS, we assessed recruitment of peripheral APCs 
to the brain in recipient mice.  Both microglia and peripheral APCs are 
CD11b+ myeloid-derived cells that are distinguished by their levels of 
CD45 expression.  Microglia are a defined CD11b+CD45intermediate 
population whereas peripheral macrophages/DC are CD11b+CD45high 
cells.   As a positive control for CNS inflammation, we analyzed APC 
recruitment to the CNS in a symptomatic EAE animal (Fig 4).  Here, we 
saw a significant number of peripheral APCs in the brain, in addition to  
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Fig 4.  Peripheral APC are recruited to the CNS in EAE.  C57BL/6 
mice were immunized with MOG35-55 in CFA + PTx to induce EAE.   Brain 
cells from an asymptomatic mouse (score 0) and a symptomatic mouse 
(score 2.5) were stained for CD45 and CD11b.  
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resident microglia.  In comparison, an immunized asymptomatic mouse 
with no visible signs of EAE did not exhibit recruitment of antigen 
presenting cells from the periphery (Fig 4).   When we examined the 
brains of adoptive transfer recipients, we saw little recruitment of 
macrophages or DCs from the periphery (Fig 5).  These results 
demonstrate a lack of inflammation in the CNS of our adoptive transfer 
mice, despite the presence of HuD-specific CD8 T cells and cognate 
antigen behind the blood-brain barrier.    Trafficking of activated T cells 
to the brain is not antigen-dependent, as activated T cells are readily 
allowed access to this compartment, presumably as a means of 
monitoring the CNS for infection.   Initiation of an inflammatory response 
behind the blood brain barrier requires the recruitment of peripheral 
antigen presenting cells and up-regulation of antigen processing and 
presentation machinery.    
 
HuDp321-specific CD8 T cells in the inflamed CNS are not sufficient for the 
induction of neuronal degeneration   
HuD-specific CD8 T cells were unable to induce inflammation and 
neuronal degeneration.  In order to generate an inflammatory 
environment in the CNS, we induced EAE in recipient animals before the 
adoptive transfer of HuD-specific CD8 T cells (Fig 6).  C57BL/6 mice 
were immunized with MOG peptide to initiate EAE.  Prior to the onset of 
clinical disease, HuD- or β-gal-specific CD8 T cells were adoptively  
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Fig 5.   Peripheral APC are not recruited to the CNS after adoptive 
transfer of HuD-specific CD8 T cells.  Rag-/- mice received an adoptive 
transfer of Thy1.1 HuD-specific (red mice) or Bgal-specific (blue mice) 
CD8 T cells (as in Fig 1a). One month later, cells from the brains of 
perfused recipients were stained for CD45 and CD11b.   Numbers 
indicate percentages of CNS infiltrating APCs. 
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Fig 6. Adoptive transfer of HuDp321-specific CD8 T cells into EAE 
mice.  C57BL/6 mice were immunized with MOG35-55 in CFA + PTx to 
induce EAE. 6 days later, mice received 5 x 106 in vitro stimulated 
Thy1.1 HuDp321-specific or Bgalp96-specific CD8 T cells (i.v.) with 2 x 
106 cognate peptide-pulsed DC (i.v), PTx, and IL-2.   
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transferred into MOG-immunized recipients.   Mice exhibited clinical 
symptoms of demyelination, with no exacerbation or mitigation of disease 
by transferred HuD-specific T cells.  When brain and spinal cord sections 
were examined by histology, there were visible signs of inflammation and 
infiltration by immune cells, however no neuronal damage was observed 
(Fig 7).   Brain cells from recipients exhibited marked up-regulation of 
MHC I and MHC II molecules on resident microglia and infiltrating 
peripheral APCs (Fig 8).    Induction of EAE was effective at generating 
inflammation in the CNS, however this was not sufficient for the 
initiation of neuronal degeneration by HuD-specific CD8 T cells.   
 
Summary 
Upon adoptive transfer, HuD-specific CD8 T cells were able to traffic to 
the CNS.  Recruitment to the brain was not antigen-dependent, as both 
HuD- and βgal-specific CD8 T cells were present behind the blood brain 
barrier.    Transferred T cells isolated from spleens of recipient animals 
were positive for both Thy1.1 and CD8 markers.   When lymphocytes 
from the brain were analyzed, Thy1.1 transferred T cells were lacking in 
expression of the CD8 coreceptor.   Downregulation of the CD8 
coreceptor was possibly due to the immunosuppressive environment in 
the CNS, which is designed to limit the generation of inflammatory 
immune responses.    Any suppression of transferred CD8 T cells within 




Fig 7. Adoptive transfer of HuDp321-specific CD8 T cells into EAE 
mice does not result in neuronal degeneration.  EAE was induced in 
C57BL/6 mice before adoptive transfer of Thy1.1 HuD-specific or Bgal-
specific CD8 T cells (as described in Fig 6).  Mice were sacrificed when 
disease reached a clinical score of 2 (partial hind limb paralysis) and 
perfused with PBS followed by paraformaldehyde.  Brain and spinal cord 
sections were fixed in formalin.  Fixed tissues were sent to Charles River 
for analysis.    (a) H & E staining on a representative mouse that received 
HuD-specific T cells.  (b) H & E staining on a representative mouse that 
received Bgal-specific T cells.  
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Fig 8.  MHC I and II are upregulated in the CNS during EAE.   EAE 
was induced in C57BL/6 mice before adoptive transfer of Thy1.1 HuD-
specific or Bgal-specific CD8 T cells (as described in Fig 6).   Brain cells 
from two representative mice, both with a clinical score of 2.5, were 
stained for MHCI and MHC II expression.  Histograms show MHC I and 
MHC II expression on microglia cells (CD11b+CD45int) and peripheral 
APC (CD11b+CD45hi).  In red is a mouse that received HuD-specific T 
cells, in blue is a mouse that received Bgal-specific T cells. 
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by stimulation with cognate peptide.  Both HuD- and βgal-specific CD8 T 
cells isolated from the CNS were able to secrete IFNγ in response to 
cognate peptide in an ELISPOT assay.     Although HuD-specific CD8 T 
cells were able to traffic to the brain when transferred into Rag-/- 
recipients, we saw no signs of inflammation or neuronal loss in the CNS, 
despite the presence of HuD antigen and the absence of regulatory T cells 
in these hosts.   Restimulation of infiltrating lymphocytes is an important 
step in the generation of CNS inflammation, and depends on peripheral 
APC recruitment and upregulation of MHC molecules on resident 
microglia.  The inability of HuD-specific CD8 T cells to induce disease 
was likely due to a lack of restimulation behind the blood brain barrier.  
We saw no recruitment of APCs to the CNS, and no upregulation of MHC 
molecules on microglia in our adoptive transfer recipients.   In order to 
artificially create an inflammatory environment for transferred HuD-
specific T cells, we generated EAE in recipient mice.   These mice 
displayed characteristic clinical signs of demyelinating disease, and 
exhibited high expression of MHC I and MHC II molecules on both 
microglia and peripheral APCs in the CNS.    Examination of CNS tissue 
revealed a lack of neuronal degeneration but obvious areas of infiltration, 
and mice did not appear visibly affected by the transfer to activated HuD-




CHAPTER VI. IDENTIFICATION OF HUMAN HLA CD8 T CELL 
EPITOPES OF HUD 
 
Introduction 
We sought to identify clinically relevant human HuD epitopes in order to 
better understand and diagnose anti-Hu syndrome.   Our immediate goal 
was to use the results of this comprehensive peptide screen to design 
HuD-specific tetramers that would allow us to visualize and characterize 
HuD-specific CD8 T cells in the blood and cerebrospinal fluid of patients.  
Using a novel approach to epitope discovery developed by Beckman 
Coulter, we screened the entire HuD peptide library over 8 human HLA 
MHC I alleles.  Each HuD peptide was evaluated based on its affinity and 
off-rate for individual MHC alleles.    Based on the results of this screen, 
peptides were given a numerical score and ranked, with higher scores 
signifying more likely CD8 T cell epitopes.    Data for all 8 human HLA 
MHC alleles were acquired.  We chose to evaluate peptides restricted to 
the HLA A2.1 and HLA A3.1 alleles, since these are two of the most 
prevalent MHC alleles in the western population.    Tetramers were 
designed for each potential epitope, which were used to analyze patient 
blood for the presence of HuD-specific CD8 T cells.   This provided 
irrefutable evidence of HuD-specific CD8 T in the blood of patients with 




A comprehensive screen to identify human HuD epitopes 
To identify human epitopes of HuD, we generated a complete HuD 
peptide library consisting of 386 overlapping nonamers, including 
peptides derived from all known splice variants of the protein.  Each 
peptide was screened for its ability to bind to recombinant HLA MHC I 
molecules.  We screened the entire HuD peptide library over 8 different 
HLA alleles, including HLA A2.1 and HLA A3.1.  Together, HLA A2.1 and 
HLA A3.1 are carried by roughly 40% of the Caucasian population, 
making them two of the most common MHC I alleles.  For this reason, 
our studies focused on epitopes presented by these specific MHC 
molecules, although future work will extend to all 8 alleles examined in 
the screen.   Peptides were ranked according to a final iScore, which was 
generated based on binding, affinity and off-rate measurements.  We 
identified 39 HLA A2.1-restricted peptides with significant iScores.  To 
narrow down this list of potential HLA A2.1 HuD epitopes, we reasoned 
that pathologically relevant HuD-specific CD8 T cells should recognize 
peptides that are not shared between HuD and its closely related family 
member HuA.  As previously discussed, HuA is a ubiquitously expressed 
protein found throughout the body.  Moreover, patients with the Hu 
syndrome generate an immune response that targets the nervous system 
exclusively, leaving peripheral tissues unaffected.  This lack of peripheral 
autoimmunity suggests that relevant disease epitopes are not common to 
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HuA.  Of the 39 HLA A2.1-restricted peptides, 20 were different in 
sequence from HuA and therefore chosen for further evaluation. 
 
HuDp157 is a naturally processed A2.1 epitope  
In order to determine which of these 20 potential HuD HLA A2.1-
restricted peptides are naturally processed and presented epitopes, we 
took advantage of the AAD transgenic mouse that expresses human HLA 
A2.1 molecules.   Because HuD is highly conserved, with only two amino 
acid differences between the mouse and human proteins, we were able to 
immunize A2.1 transgenic mice with adenovirus-HuD to assess natural 
processing and presentation without fear of priming responses to neo-
epitopes.   AAD mice were immunized with adenovirus-HuD in 
combination with pertussis toxin to allow for natural processing and 
presentation of HuD epitopes onto HLA A2.1 molecules and subsequent 
CD8 T cell priming in vivo.  CD8 T cells from immunized mice were 
stimulated in vitro with each of the 20 peptides and assessed for their 
ability to secrete IFNγ in response to cognate peptide in an ELISPOT 
assay (Fig 1).  Of the 20 potential epitopes, 11 were able to elicit IFNγ 
secretion from CD8 T cells in an antigen-dependent manner.   It seemed 
unlikely that all 11 peptides represented true HuD epitopes, and we 
therefore chose to assess natural processing and presentation in a more 
stringent assay.  We re-screened CD8 T cells from immunized mice in an 
ELISPOT assay using syngeneic stimulators infected with adenovirus- 
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Fig. 1.    Screening HLA A2.1 restricted HuD peptides in AAD mice.  
Spleen cells from AAD mice immunized with AdVHuD + PTx were 
stimulated in vitro with the peptides indicated on the x-axis.  After ten 
days of stimulation, purified CD8 T cells were plated in an IFNγ ELISPOT 
with EL4-A2.1 cells pulsed with relevant or irrelevant peptide. 
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HuD (Fig 2).  In this way, HuD epitopes were naturally processed and 
presented onto HLA A2.1 molecules both for priming in vivo and for 
antigen-specific IFNγ secretion in vitro.    Because AAD mice retain 
expression of mouse H-2b MHC I molecules, we used three sets of 
syngeneic stimulators in the ELISPOT assay to ensure that IFNγ 
secretion was in response to peptides presented on HLA A2.1 rather than 
mouse Db or Kb molecules.   Syngeneic stimulators consisted of kidney 
cells from AAD, HHD, or C57BL/6 mice.    Again, AAD mice express both 
mouse MHC I molecules as well as human A2.1, whereas HHD mice are 
deficient for mouse MHC I and express only human A2.1.  C57BL/6 mice 
are wild type H-2b mice that express Kb and Db molecules.    Kidney cells 
derived from each of these three strains were infected with either 
adenovirus-HuD or, as a control, adenovirus-GFP.  A true HLA A2.1-
restricted epitope of HuD should elicit a response from HuD-specific CD8 
T cells only when presented by either AAD or HHD kidney cells infected 
with adenovirus-HuD.  IFNγ secretion should not be seen in response to 
C57BL/6 kidney cells infected with adenovirus-HuD, as this would imply 
presentation by mouse H-2b MHC I.    Of the 11 peptides that screened 
positive in the initial ELISPOT assay, only two elicited IFNγ secretion in 
response to AAD and HHD kidney cells infected with adenovirus-HuD 
(Fig. 2).   Peptides 157 and 287 appeared to be true A2.1-restricted HuD 
epitopes, and we therefore sought to generate tetramers for both 
peptides.   Due to technical difficulties, p287-specific tetramers were  
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Fig. 2.    HuDp157 is a naturally processed A2.1-restricted epitope.    
CD8 T cells purified from spleen stimulation cultures were tested for 
their ability to recognize whole HuD protein processed and presented by 
primary kidney cells infected with AdVHuD (or AdVGFP as a negative 
control).  CD8 T cells specific for HuDp157, HuDp287, or HuDp315 were 
plated in an IFNg ELISPOT with infected kidney cells from AAD mice (top 
panel), HHD mice (middle panel), or wild type mice (bottom panel). 
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impossible to create and after several rounds of discussion with iTopia 
consultants from Beckman Coulter, we chose to discount p287 as a real 
HuD epitope.   
 
HuDp157 specific T cells are present in the blood of Hu patients 
We designed HLA A2.1-restricted tetramers specific for HuDp157 in order 
to screen the blood of patients with the Hu syndrome for the presence of 
HuDp157-specific CD8 T cells.   After a single round of in vitro 
stimulation with p157, we detected a population of HuDp157-specific 
CD8 T cells from an HLA A2.1+ Hu patient but not from HLA A2.1+ 
normal donors (Fig 3).   Normal donors exhibited an expanded population 
of CD8 T cells specific for common viral epitopes of influenza or CMV (Fig 
3).  This was the first direct proof of HuD-specific T cells in the blood of 
an Hu patient.  Taken together, these results support the hypothesis that 
CD8 T cells play an important pathological role in autoimmune 
neurologic degeneration.   
 
HuDp157-specific CD8 T cells from patients are functional cytotoxic T cells 
 Our model of disease pathogenesis depends on the destruction of HuD-
expressing tumor cells and neurons by effector HuD-specific CD8 T cells.  
To show that CD8 T cells isolated from Hu patients are capable of lysing 
HuDp157-expressing targets, we performed a CTL assay with tetramer-












Fig 3.  HuDp157-specific T cells are present in Hu patient blood.    
Peripheral blood T cells from one Hu patient and four normal donors 
were expanded in vitro with HuDp157 and stained with HuDp157-specific 
or irrelevant peptide-specific (negative) tetramer.   As a control, 
peripheral blood T cells were expanded with M1 or CMV peptide and 





















patients because previous attempts to assess the function of HuD-
specific T cells using bulk T cell cultures were unsuccessful.  We 
reasoned that the frequency of HuD-specific T cells isolated from patient 
blood was too low for detection in our assays.  To overcome this 
limitation, we stimulated patient T cells in vitro with p157 prior to sorting 
tetramer-positive CD8 T cells from bulk T cell stimulation cultures. 
Tetramer-sorted HuDp157-specific CD8 T cells from two individual Hu 
patients were used in CTL assays with cognate or irrelevant peptide-
pulsed targets.   HuDp157-specific CD8 T cells from both patients were 
able to lyse target cells in an antigen-dependent manner (Fig 4).    These 
results strengthen our model of CD8 T cell mediated disease 
pathogenesis, and mimic the results from our mouse system.   Both 
human and mouse HuD-specific CD8 T cells are able to act as cytotoxic 
T cells, but require isolation and in vitro stimulation in order to expand 
and acquire effector function.   
 
HLA A3.1 restricted HuD-specific CD8 T cells from patients are functional 
cytotoxic T cells 
To identify clinically relevant HLA A3.1 restricted epitopes of HuD, we 
used the five top-scoring peptides from the iTopia screen in patient 
experiments.  Because there were fewer candidate peptides for A3.1 than 
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for A2.1, we chose to move directly to A3.1+ patient assays.  T cells from 
four A3.1+ Hu patients were used to screen the A3.1-restricted candidate  
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Fig. 4.   HuDp157-specific T cells from patients are functional 
cytotoxic T cells.  (a) HuDp157 and influenza M1 tetramer+ T cells from 
an Hu patient were expanded in vitro with peptide, followed by FACS 
sorting of the tetramer+ population.  Tetramer+ cells were allowed to 
recover with irradiated, peptide-pulsed, autologous PBMC and IL-2.  
After recovery, T cell lysis was measured in a CTL assay with peptide-
pulsed T2 cells.  (b) lytic functions of HuDp157 and influenza M1 




peptides.   CD8 T cells were cultured for 8 days with autologous peptide-
pulsed DCs to expand antigen specific T cells before their use in tetramer 
and CTL assays.    Of the five A3.1 candidate peptides, HuDp133 was the 
only peptide capable of expanding CD8 T cells from patient blood (Fig 5).   
One out of four Hu patients exhibited expansion of HuDp133 specific T 
cells (Fig 5).    In comparison, none of the neurologically normal A3.1+ 
control patients had an expanded HuDp133 population, but all 
demonstrated expansion of influenza specific T cells.      The lack of 
HuDp133-specific CD8 T cells in three of the four A3.1+ Hu patients is 
not surprising, considering that these patients have other HLA MHC I 
alleles in addition to A3.1, and may generate HuD-specific responses to 
epitopes restricted to these other alleles.   Expanded HuDp133-specific 
CD8 T cells were assessed for the ability to lyse target cells expressing 
cognate peptide (Fig. 6).  Bulk T cells were stimulated in vitro with each of 
the five A3.1-restricted HuD peptides before use in a CTL assay.    
HuDp133-specific CD8 T cells were able to lyse targets in an antigen-
dependent manner, demonstrating that HLA A3.1-restricted HuD-specific 
T cells are functional effectors present in Hu patient blood. 
 
Summary 
CD8 T cells are the effector cells responsible for the destruction of 
neurons and tumor cells in our model of the Hu syndrome.  In order to 












Fig. 5.  HuDp133 is an HLA A3.1-restricted epitope of HuD.  Tetramer 
staining of T cells from four different HLA A3.1 Hu patients and two 
normal donors after expansion with five A3.1-restricted HuD peptides.  T 
cells were stained with tetramer specific for cognate A3.1 peptide or an 
irrelevant tetramer.  As a positive control, T cells were expanded with the 
HLA A.3.1-restricted epitope of influenza nucleoprotein (NP) and stained 






















Fig. 6.   HuDp133-specfic T cells are functional cytotoxic T cells.   T 
cells from an A3.1+ Hu patient (Hu #1 in figure 5) were expanded in vitro 
with five A3.1-restricted HuD peptides.  After expansion, cells were 
stained with tetramer specific for cognate HuD peptide or irrelevant 
peptide.  Lytic function of the expanded T cells was measured in a CTL 
assay with T2 cells pulsed with cognate HuD peptide or irrelevant 








isolate and characterize HuD-specific CD8 T cells from patients.   This 
required the identification of human CD8 T cell epitopes of the protein.   
To this end, we performed a comprehensive screen of the entire HuD 
peptide library over 8 human HLA alleles.   A list of potential epitopes 
was generated from the screen, which lead to the discovery of two human 
CD8 T cell epitopes of HuD.   Tetramers for these two epitopes were used 
to examine the blood of Hu patients for the presence of HuD-specific CD8 
T cells.  We found an expanded population of HuD-specific CD8 T cells in 
Hu patients but not in normal donors, indicating that these T cells play a 
role in disease development.  Tumor immunity and neurodegeneration in 
the Hu syndrome require lysis of HuD-expressing cells by cytotoxic T 
cells.  We therefore assessed the lytic ability of HuD-specific CD8 T cells 
isolated from the blood of Hu patients.    We found that A2.1- and A3.1-
restricted HuD-specific CD8 T cells from patients were efficient at 
destroying target cells that expressed cognate HuD peptide.  This 









CHAPTER VII. DISCUSSION 
 
Development of neuronal autoimmunity in patients with SCLC appears 
to depend on a loss of tolerance to the onconeural antigen HuD (Fig 1).    
This destructive immune response against HuD-expressing neurons is 
also able to mediate impressive tumor immunity.  Tumor immunity and 
neuronal autoimmunity are not always coupled, since a significant 
number of SCLC patients mount an immune response to their cancer 
that correlates with limited stage tumors and better prognoses in the 
absence of neurologic disease (Dalmau, Furneaux et al. 1990).    
Understanding the mechanisms responsible for tolerance induction to 
HuD, and how tolerance is broken in the presence of an HuD-expressing 
tumor, are of great clinical significance with regard to designing better 
therapies for SCLC.      
 
In order to study tolerance to HuD in an animal model, we first identified 
the immunodominant CD8 T cell epitope of the protein in C57BL/6 mice 
through an exhaustive screen of the entire HuD peptide library.   We 
found CD8 T cells specific for 7 peptides of the protein, and went on to 
determine which of these represented naturally processed and presented 
epitopes. This allowed for the identification of the immunodominant CD8 
T cell epitope of HuD, p321.  HuDp321-specific CD8 T cells were 
characterized in functional and phenotypic assays.  We found that these  
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Fig 1. Revised model of anti-Hu syndrome.  HuD-specific T cells are 
normally tolerized to the HuD protein.  The presence of a small cell lung 
cancer tumor that expresses HuD is able to break tolerance to the HuD 
antigen in 15% of patients, resulting in an immune response against the 
cancer.  In 01% of patients, this immune response is also able to traffic 




cells, once activated in vitro, were high affinity T cells capable of lysing 
targets in an antigen dependent manner.  The inability to detect these 
cells directly after immunization with recombinant adenovirus was the 
first indication that HuD-specific CD8 T cells were subject to tolerance 
induction.   Priming an effective immune response required pertussis 
toxin in combination with adenovirus-HuD followed by in vitro 
stimulation with peptide.    In vitro stimulation allowed for the expansion 
of HuD-specific CD8 T cells, and served to eliminate any suppression felt 
in vivo.   The role of pertussis toxin in our system was less clear.    It 
obviously acted as an adjuvant, enhancing the immune response to HuD 
in vivo in order to allow for further expansion in vitro.   Immunization 
with adenovirus-HuD together with in vitro stimulation in the absence of 
pertussis toxin failed to generate a detectable population of functional, 
IFNγ-secreting HuD-specific CD8 T cells, indicating that pertussis toxin 
served to quantitatively or qualitatively change the T cell response in vivo.   
Still, pertussis toxin alone was not sufficient to generate detectable IFNγ-
secreting HuD-specific cells, since T cells isolated from mice immunized 
with pertussis toxin and adenovirus-HuD did not secrete IFNγ in 
response to antigen directly ex vivo, in the absence of in vitro stimulation.    
The need for pertussis toxin together with in vitro stimulation for the 
generation of HuD-specific CD8 T cells may be the result of low precursor 
frequency in conjunction with peripheral tolerance induction.   Pertussis 
toxin might relieve some of the suppression on HuD-specific T cells in 
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vivo, but additional expansion by in vitro stimulation may be necessary 
due to low precursor frequency.   
 
Pertussis toxin has been shown to act as an adjuvant by inducing 
maturation of dendritic cells, resulting in the expansion of effector T cells 
and IFNγ production (Hou, Wu et al. 2003).  It has also been implicated 
in blocking the function of regulatory T cells, thereby promoting 
productive immune responses (Chen, Winkler-Pickett et al. 2006).     The 
means of inducing peripheral tolerance to HuD are still unclear.  Anergy 
induction or inhibition by regulatory T cells are both possible 
mechanisms of suppression of HuD-specific T cells, either of which 
would be overcome by pertussis toxin.  Our preliminary experiments 
have shown that depletion of CD4 T cells followed by adenovirus-HuD 
immunization failed to generate a detectable HuD-specific response 
directly ex vivo, implying that regulatory T cells are not responsible for 
tolerance induction.    However, CD4 T cell depletion is not a specific 
means of eliminating regulatory T cells, since the entire CD4 T cell 
population is removed, which includes helper CD4 T cells that may be 
required to assist in HuD-specific CD8 T cell priming.   Regulatory T cells 
may be responsible, in part, for inhibiting HuD-specific immune 
responses, given that HuD-specific CD8 T cells escape central tolerance 
to circulate in the periphery with relatively high affinity for antigen.  
Regulatory T cells could act to inhibit HuD-specific CD4 T cells, which 
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would in turn prevent the activation of HuD-specific CD8 T cells.  A 
coordinated response from both the CD4 and CD8 T cell arms of the 
immune system is almost certainly required for the generation of HuD-
specific autoimmunity, so that inhibition of HuD-specific CD4 T cells 
would be an important means of inducing tolerance in the periphery.    
Given that HuD is an intracellular antigen, cross-presentation of 
exogenous protein is required for the initiation of HuD-specific CD8 T cell 
responses.  CD4 T cells are necessary for effective cross-presentation to 
CD8 T cells, making their inhibition imperative to the prevention of HuD-
specific CD8 T cell-mediated neurodegeneration (Albert, Jegathesan et al. 
2001).     
 
Anergy induction is a potential mechanism of HuD-specific CD8 T cell 
suppression, which would depend on peripheral presentation of HuD to 
circulating T cells.   Presentation of HuD could involve expression of the 
protein by a non-neuronal cell type, for example a lymph node stromal 
cell, which would result in anergy induction.   We have yet to find HuD 
protein or RNA expression in any tissue outside of the nervous system, 
however it may be expressed at extremely low levels, making detection 
difficult.  The transcription factor AIRE has been implicated in regulating 
the expression of tissue-specific proteins by lymph node stromal cells for 
the purpose of inducing tolerance, so we investigated its role in 
controlling ectopic expression of HuD.   However, HuD expression did not 
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appear to be governed by AIRE.  This does not rule out the possibility 
that unidentified transcription factors exist in order to regulate 
expression of HuD and other tissue-specific proteins for the purpose of 
inducing tolerance.   In the absence of, or in addition to the ectopic 
expression of HuD by a non-neuronal cell type, HuD-expressing neurons 
may be cross-presented via DCs, resulting in cross-tolerization of HuD-
specific CD8 T cells.  However, neurons do not normally turn over, which 
makes reliance on cross-presentation for tolerance induction potentially 
dangerous.   It is possible that only pieces of neurons, in the form of 
membrane-bound blebs, are taken up by DCs for cross-tolerization of 
HuD-specific CD8 T cells.     
 
We found it useful to compare tolerance induction to HuD versus its 
related family member HuA.  Given the ubiquitous expression of HuA, we 
reasoned that tolerance to this protein should be stricter compared to 
HuD.     Patients with the Hu syndrome develop autoimmunity that is 
restricted to the nervous system but never directed against peripheral 
tissues, suggesting that effector CD8 T cells responsible for disease 
pathogenesis are unable to cross react with HuA.    Furthermore, patient 
sera react with HuB, HuC and HuD but not with HuA.  We hypothesized 
that HuA-specific T cells should be centrally tolerized, since their 
presence in circulation could lead to the generation of massive peripheral 
autoimmunity.  If HuA is subject to central tolerance induction, there 
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should not be T cells specific for any of the shared epitopes between HuD 
and HuA in the repertoire.  We compared all 7 of the potential HuD 
epitopes initially identified in our peptide screen for sequence homology 
to their corresponding HuA epitopes.  Of the 7 potential epitopes, 6 were 
different in HuA, supporting the idea that HuA is centrally tolerized.   Of 
these 7 potential epitopes, only one, HuDp321, proved to be naturally 
processed and presented by the immune system.   We compared this 
immunodominant HuD CD8 T cell epitope to its related epitope in HuA, 
peptide 268.  HuA p268 differs from HuD p321 at a single amino acid 
position.  The fourth residue is converted from an asparagine in HuD to a 
threonine in HuA.  This is a non-conserved amino acid difference, found 
at a position that is known to interact with the T cell receptor but that 
does not affect MHC binding affinity.  In order to show that HuA p268 
binds with similar affinity to MHC I compared to HuD p321, we 
performed an MHC I stabilization assay. HuA peptide bound MHC I with 
higher affinity than p321.  When mice were immunized with either the 
HuA peptide or HuD peptide emulsified in titermax adjuvant, there was a 
strong response from HuDp321-specific CD8 T cells, however we did not 
detect any HuAp268-specific T cells.   The absence of HuA-specific T cells 
strongly suggests that mice are centrally tolerized to the HuA protein.  
Conversely, the existence of T cells specific for HuD in the repertoire 
indicates that central tolerance does not apply to HuD.   Also, we have 
demonstrated that AIRE, a transcription factor involved in the induction 
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of central tolerance, does not regulate expression of HuD in mice. 
Nevertheless, we cannot exclude the possibility that HuD is subject to 
central tolerance induction via an AIRE-independent pathway, and that a 
portion of HuD-specific T cell clones are able to escape thymic deletion, 
resulting in a small precursor frequency in the periphery.    
 
The initial immune response in patients with the Hu syndrome is 
directed against HuD, since this is the only Hu family member expressed 
in SCLC.  Patients present with neurologic symptoms that affect discrete 
areas of the nervous system but often go on to develop multifocal 
neuronal degeneration.  Although all Hu patients share the characteristic 
anti-Hu antibody response that is correlated with tumor immunity and 
neuronal autoimmunity, the regions of the nervous system affected vary 
widely.  The disease begins with an acute phase and can either plateau 
to reach a state of chronic but not degenerating illness, or progressively 
worsen from the time of diagnoses until death.   These differences among 
patients reflect diverse pathways of disease progression that may be due 
to genetic and environmental factors.  Every individual has a different 
group of MHC molecules, referred to as the haplotype, which determines 
the spectrum of peptides presented to the immune system.  MHC 
haplotype can strongly influence disease susceptibility and immunity, 
and almost certainly affects the onset and development of the Hu 
syndrome.  The fact that most patients progress from neurologic 
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symptoms targeted to discrete areas of the nervous system to multifocal 
neuronal degeneration suggests that there may be epitope spread to 
generate immune responses against other Hu family members during the 
course of the disease.  The initial immune response to HuD in the 
periphery via ectopic expression of this neuronal antigen by a SCLC 
tumor might be expanded to include immune responses against other Hu 
family members.   For instance, HuD-specific CD8 T cell-mediated 
destruction of neurons that express both HuD and HuC could result in 
the activation of HuC-specific T cells, which would then mediate 
neuronal degeneration of HuC expressing neurons, resulting in 
multifocal disease.    
 
Given the high sequence homology between the Hu proteins, there may 
be a shared CD4 T cell epitope between Hu family members that 
facilitates epitope spread.   The generation of effector CD8 T cell 
responses to HuB or HuC would almost certainly depend on cognate CD4 
T cell help, since cross presentation by an APC is required.   If the initial 
immune response to HuD-expressing SCLC cells in the periphery results 
in the activation of CD4 T cells that recognize a shared Hu epitope, these 
same CD4 T cells would be primed to assist in the generation of an 
immune response against other Hu family members.   In Hu patients, we 
detect anti-Hu antibodies that recognize HuB, HuC, and HuD, indicating 
that the B cell epitope of the protein is conserved among family members.   
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Whether regulatory T cells, as opposed to helper CD4 T cells, recognize a 
shared epitope is still unclear.  We have shown that HuC expression is 
not required for tolerization of HuD-specific CD8 T cells.  When HuC-
deficient animals were immunized with adenovirus-HuD, there was no 
detectable HuD-specific response directly ex vivo, whereas HuD-deficient 
mice showed a strong ex vivo response to HuDp321.   It would seem 
efficient to generate regulatory T cells specific for a shared Hu epitope in 
order to maintain tolerance to the Hu protein family, however our results 
do not support this hypothesis.   What is clear is the requirement for 
HuD expression for tolerization of HuD-specific CD8 T cells.   Either HuD 
expression serves to generate regulatory T cells specific for a CD4 epitope 
that is unique to the protein, or is directly responsible for inducing 
anergy in HuD-specific CD8 T cells.  The CD8 T cell epitope of HuD is not 
shared by other Hu family members, so that anergy induction would 
necessarily require expression of HuD but not other Hu family members.   
 
The presence of a SCLC tumor in the periphery that expresses HuD 
appears to be the initial trigger for the generation of an anti-Hu immune 
response.    This pocket of antigen, outside of the nervous system, is able 
to break tolerance to HuD and elicit effective anti-tumor immunity.   The 
steps required for the loss of tolerance are still unknown.    Certain 
cytokines or growth factors produced by SCLCs may help to overcome 
suppression and prime HuD-specific lymphocytes.   Genetic differences 
140 
may also determine which SCLC patients are able to generate anti-Hu 
antibodies and tumor immunity.  Given that 15% of SCLC patients 
manufacture anti-Hu antibodies, the loss of tolerance is not a 
particularly rare event.  What is rare is the generation of neuronal 
autoimmunity, as only .01% of SCLC patients succumb to neurologic 
disease.  There is obviously an additional, and more infrequent event 
that distinguishes patients with autoimmune neurodegeneration from 
those with low titer antibody and better tumor immunity in the absence 
of neurologic disease.    Perhaps there are multiple mechanisms of 
inducing tolerance to HuD in order to safeguard against neuronal 
degeneration.   One form of tolerance may be overcome in neurologically 
normal SCLC patients with anti-Hu antibodies, whereas most or all are 
broken in anti-Hu patients, allowing for the development of neuronal 
autoimmunity.    The fact that Hu patients generate high titer antibodies 
to Hu, whereas neurologically normal patients produce low titer 
antibodies, indicates a qualitative or quantitative difference in the 
immune response in these two groups.    Since both sets of patients are 
able to generate tumor immunity in the periphery, the distinguishing 
mechanism or event that translates to neurologic disease would be likely 
to occur in the nervous system.  HuD is expressed in peripheral neurons 
as well as in the CNS, so it is unclear if this distinguishing event 
necessarily occurs behind the blood brain barrier.  It may instead 
happen near peripheral neurons, and could require neuronal death or 
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inflammation in order to prime a strong and lasting immune response to 
HuD.   Patients with Hu antibodies generate a primary response to HuD 
in the periphery that seems to depend on the ectopic expression of this 
neuronal protein by a SCLC tumor.  The subsequent neuronal 
autoimmunity in Hu patients should depend on the recognition of HuD 
in the nervous system via cross presentation by a professional APC.   A 
concurrent infection that generates inflammation would help to overcome 
tolerance to the protein, resulting in a degenerative immune response 
against HuD expressing neurons.     
 
Patients with SCLCs that are able to generate natural tumor immunity in 
the absence of neurologic disease offer invaluable insight into how the 
body can recognize and destroy cancer.    In order to understand and 
harness this natural tumor immunity for treatment of SCLC, it is 
imperative that we understand the differences between neurologically 
normal SCLC patients and patients with the Hu syndrome to ensure that 
therapy does not cause autoimmune neurodegeneration.  Understanding 
the mechanisms behind autoimmune neurodegeneration requires the 
creation of a mouse model of CNS disease mediated by HuD-specific T 
cells.   To this end, we designed an adoptive transfer system to study T 
cell mediated neuronal degeneration, using in vitro stimulated HuDp321-
specific CD8 T cells.   We found that upon adoptive transfer into 
syngeneic recipients, HuDp321-specific CD8 T cells persisted up to one 
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month post transfer and were able to traffic to the CNS.  However, 
trafficking to the CNS was not antigen-dependent, as β-galactosidase-
specific CD8 T cells were also found in the brain.   It has been shown in 
other experimental systems that activated T cells routinely traffic to the 
CNS in order to monitor this compartment for infection.  Once inside the 
CNS, both HuD-specific and βgal-specific CD8 T cells downregulated the 
CD8 co-receptor.  Downregulation of the CD8 co-receptor is arguably a 
means of suppressing activated T cells within the brain in order to 
protect against inflammation and tissue damage.  HuD-specific and βgal-
specific CD8 T cells in the CNS were not permanently suppressed, 
however, since these cells could secrete IFNγ in response to peptide in an 
ELISPOT assay.   Despite the presence of both activated HuD-specific 
CD8 T cells and cognate antigen in the CNS, we saw no neurologic 
disease in our experimental system.   The lack of disease appeared to be 
due, in part, to a lack of inflammation behind the blood brain as there 
was no recruitment of peripheral APCs or upregulation of MHC molecules 
in the brain.    As a means of artificially creating CNS inflammation in 
our adoptive transfer recipients, we induced EAE in host animals prior to 
the transfer of HuD-specific CD8 T cells.   This resulted in clinical signs 
of demyelination and characteristic recruitment of peripheral APCs 
together with upregulation of MHC I and II expression on resident 
microglia.   Nevertheless, recipient animals exhibited no signs of 
neuronal degeneration by histology.     The most obvious explanation for 
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the lack of disease is the absence of HuD-specific CD4 T cells in this 
model.    
 
Many models of brain disease involve recruitment of peripheral APCs to 
the CNS. Reactivation of T cells via DCs behind the blood brain barrier is 
an initiating step in the development of CNS inflammation (Becher, 
Bechmann et al. 2006). Microglia are also activated during the 
inflammatory response by upregulating expression of MHC molecules in 
order to assist in the maintenance of inflammation.   Given that HuD is 
an intracellular neuronal antigen, cross presentation by an APC is 
presumably required for reactivation of T cells behind the blood brain 
barrier in order to initiate an inflammatory response that ultimately 
results in destruction of HuD-expressing neurons.    Cross-presentation 
to CD8 T cells requires CD4 T cell help, so that the presence of an HuD-
specific CD4 T cell in the brain is necessary for disease pathogenesis.  
Even after the initial reactivation of T cells behind the blood brain 
barrier, subsequent stages of disease depend on presentation of antigen 
by microglia, which become active participants in the inflammatory 
reaction.  Exacerbation of disease by microglial antigen presentation to 
HuD-specific CD8 T cells in the parenchyma would also require cross 
presentation and CD4 T cell help.    The need for CD4 T cells in CNS 
disease pathogenesis is indicated by the spontaneous development of 
autoimmune-mediated demyelination in transgenic mice that 
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constitutively express the costimulatory molecule B7.2 on resident 
microglia.  In this model, microglia are permanently activated in the CNS, 
which leads to spontaneous CD8 T cell-mediated demyelination 
(Brisebois, Zehntner et al. 2006).  Constitutive expression of B7.2 on 
microglia may eliminate the need for CD4 T cells if CD4 T cells are 
normally important for the expression of costimulatory molecules on 
microglia.   In this model, antigen-specific CD4 T cell recognition of 
MHC-peptide complexes on resident microglia results in upregulation of 
costimulatory molecule expression on microglia.  Activated microglia are 
then able to productively interact with CD8 T cells in the CNS and 
maintain a state of inflammation behind the blood brain barrier.    In 
transgenic mice that constitutively express B7.2 on microglia, the need 
for CD4 T cells is eliminated since costimulatory molecule expression is 
permanently induced.   
 
Our model of autoimmune-mediated neurologic disease does not include 
a CD4 T cell component.  The CD4 T cell epitope of HuD is currently 
unknown, and therefore the isolation and characterization of HuD-
specific CD4 T cells is difficult.    In order to generate autoimmune-
mediated neurologic disease, it may be necessary to transfer HuD-
specific CD8 T cells together with cognate CD4 T help.    In addition, the 
production of a transgenic mouse expressing the HuDp321-specific T cell 
receptor will be an invaluable reagent.     It may be possible to bypass the 
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need for CD4 T cells by transferring a sufficient number of clonal HuD-
specific CD8 T cells that have been stimulated in vitro.  Transfer of CD8 T 
cells 2 days after in vitro stimulation, when the cells are at their peak of 
activation, may also help to eliminate the need for cognate CD4 T cell 
help.    Ultimately, the generation of brain disease by HuD-specific T cells 
that have been primed by a tumor expressing HuD in the periphery will 
be the most informative model of autoimmune-mediated neuronal 
degeneration.    To date, there is no naturally occurring HuD-expressing 
tumor line.    It is possible to transfect a tumor line with the HuD gene, 
however protein expression will most likely exceed physiological levels, 
which may affect T cell priming in vivo.     In addition, transfection with 
the HuD gene is problematic, since HuD is a biologically active protein 
and most tumor cells will not tolerate its expression.   
 
The ultimate goal of our studies on the Hu syndrome is to design better 
diagnostic and therapeutic tools for the treatment of this aggressive form 
of autoimmune neurodegeneration.  In our model of disease 
pathogenesis, destruction of HuD expressing tumor cells and neurons 
requires antigen-specific recognition and lysis by HuD-specific CD8 T 
cells.   Isolation and characterization of HuD-specific CD8 T cells from 
patients required the identification of human CD8 T cell epitopes of the 
protein.   To this end, we performed a comprehensive screen of the entire 
HuD peptide library over 8 human HLA alleles.   A list of potential 
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epitopes was generated, which lead to the discovery of two human CD8 T 
cell epitopes of HuD.   Tetramers for these two epitopes were used to 
examine the blood of Hu patients for the presence of HuD-specific CD8 T 
cells.  We found an expanded population of HuD-specific CD8 T cells in 
Hu patients but not in normal donors, indicating that these T cells play a 
role in disease development.  Tumor immunity and neurodegeneration 
require lysis of HuD-expressing cells.  We therefore assessed the lytic 
ability of HuD-specific CD8 T cells isolated from the blood of Hu patients 
in a CTL assay.    We found that HuD-specific CD8 T cells from patients 
were efficient at destroying target cells that expressed cognate HuD 
peptide.  These results support our model of disease pathogenesis and 
allow us to ask the important question of whether there are HuD-specific 
CD8 T cells in patients with low titer antibody that are able to generate 
tumor immunity without neurologic disease.  If these patients are found 
to harbor HuD-specific CD8 T cells, this would suggest that tolerance is 
broken in both groups of patients with anti-Hu antibodies, regardless of 
their neurologic state.   Breaking tolerance to HuD would allow for an 
effective immune response to SCLC in the periphery and subsequent 
tumor immunity.  The development of neurologic disease in Hu patients 
would require an additional step that translates the peripheral response 
against HuD expressing tumor cells into an inflammatory autoimmune 
response against HuD expressing neurons.     
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SCLC is a disease that affects heavy smokers.  It would also be extremely 
informative to examine the blood of tumor-free long-term heavy smokers 
for the presence of HuD-specific CD8 T cells.   If these cells were present 
in this population, we could infer that HuD-specific CD8 T cells provided 
effective protection from the growth of SCLC.  Our goal is to harness the 
natural tumor immunity generated in patients with anti-Hu antibodies 
for the treatment of SCLC tumors, all of which express the HuD antigen.  
If HuD-specific CD8 T cells are expanded in heavy smokers and in 
neurologically normal patients with Hu antibodies, this would provide a 
strong impetus for the generation of SCLC immunotherapy based on 
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